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PERUBAHAN AWAL DAN LEWAT DALAM TINDAK BALAS 
PENGENDURAN DAN PENGECUTAN BERPERANTARA-ENDOTELIUM  
DI DALAM SALUR DARAH KECIL PADA TIKUS DIABETES 
 
ABSTRAK 
Diabetes berhubungkait dengan komplikasi salur darah kecil dan besar yang 
menyumbang kepada disfungsi lapisan endotelium dan membawa kepada penyakit 
kardiovaskular. Disfungsi endotelium (ED) dicirikan oleh gangguan pengenduran 
berperantara-endotelium dan peningkatan pengecutan-berperantara-endotelium. Sel 
endotelium menghasilkan faktor-faktor yang menyebabkan pengenduran dan 
pengecutan endotelium. Peranan faktor-faktor ini di dalam salur darah kecil tidak 
dicirikan dengan baik. Terdapat tiga objektif utama di dalam kajian ini; pertama 
adalah untuk mengetahui sumbangan nitrik oksida (NO), prostasiklin, 
hiperpolarisasi berperantara-endotelium (EDH) dan reseptor thromboxane (TXA2) 
dalam pengenduran dan pengecutan berperantara-endotelium di dalam salur darah 
kecil tikus diabetes; kedua, untuk mengetahui ekspresi enzim dan reseptor yang 
terlibat dalam pengantaraan tindak balas endotelium dan akhirnya untuk 
mengetahui perubahan awal (2 minggu) dan lewat (10 minggu) pada tindak balas 
fungsi and molekular di dalam salur darah kecil tikus diabetes. Kajian in melibatkan 
empat kumpulan kajian: tikus normal 2-minggu, tikus diabetes 2-minggu, tikus 
normal 10-minggu dan tikus diabetes 10-minggu (n=15 ekor tikus bagi setiap 
kumpulan). Kajian ke atas fungsi salur darah ditentukan dengan menggunakan 
myograph dawai. Sumbangan setiap EDRF (NO, prostasiklin dan EDH) dan 
reseptor TXA2 dalam pengenduran dan pengecutan berperantara-endotelium dinilai 




oksida endotelium (eNOS), siklooksigenase-1 (COX-1) dan siklooksigenase-2 
(COX-2), sintase prostasiklin (PGIS), reseptor prostasiklin (IP), reseptor TXA2 dan 
sintase TXA2 ditentukan dengan pemblotan Western dan imunohistokimia. 
Pengenduran berperantara-endotelium berkurangan secara signifikan dalam tikus 
diabetes 2-minggu [Rmak; 73.49 (11.04)% vs 89.32 (10.03)%, p=0.002] dan tikus 
diabetes 10-minggu [Rmak; 58.84 (18.79)% vs 89.32 (10.03)%, p<0.01] masing-
masing berbanding dengan tikus normal 2-minggu. Pengenduran berperantara–NO 
berkurangan dalam tikus diabetes 10-minggu berbanding dengan tikus normal 2-
minggu (p<0.001) dan tikus normal 10-minggu (p<0.001). Pengenduran 
berperantara-EDH berkurangan dalam tikus diabetes 10-minggu berbanding dengan 
tikus normal 2-minggu (p=0.012) dan tikus normal 10-minggu (p=0.017). 
Kemorosatan pengenduran kepada prostasiklin dilihat dalam tikus diabetes 10-
minggu berbanding tikus normal 2-minggu (p<0.001) dan tikus diabetes 2-minggu 
(p=0.033). Pemblotan Western dan imunohistokimia menunjukkan diabetes 
mengurangkan ekpresi protein eNOS, reseptor IP dan PGIS di dalam arteri ekor 
tikus. Dalam pengecutan berperantara-endotelium, peningkatan secara signifikan  
dilihat dalam tikus diabetes 10-minggu [Emak; 113.73 (51.32)% vs 34.80 (21.00)%,   
p<0.001], trend peningkatan dilihat dalam tikus diabetes 2-minggu [Emak; 71.80 
(46.02)% vs 34.80 (21.00)%, p<0.058] berbanding dengan tikus normal 2-minggu. 
Peningkatan secara signifikan di dalam kedua-dua pengecutan berperantara-COX-1 
dan COX-2, dan pengecutan berperantara-reseptor TXA2 dilihat dalam tikus 
diabetes 10-minggu. Trend peningkatan pada ekspresi protein COX-2 dan reseptor 
TXA2 diperhatikan dalam tikus diabetes 10-minggu, dan ini menyokong dapatan 
kajian fungsi. Ringkasannya, pengenduran dan pengecutan berperantara-endotelium 




teruk dengan diabetes yang berpanjangan. Sehubungan itu, pencegahan awal 



























EARLY AND LATE CHANGES IN ENDOTHELIAL DEPENDENT 
VASCULAR RELAXATION AND CONTRACTION RESPONSES IN THE 
MICROCIRCULATION OF DIABETIC RATS.  
 
ABSTRACT 
  Diabetes is associated with micro and macrovascular complications which 
contributes to endothelial dysfunction (ED) and leads to cardiovascular diseases. 
ED is characterized by impairment of endothelium-dependent relaxation and 
increases in endothelium-dependent contraction. The endothelial cells release 
factors that cause endothelial relaxation and contraction. The role of these factors in 
the microvasculature of diabetes is not well characterized. There were three main 
objectives of this study; firstly, to determine the contribution of nitric oxide (NO), 
prostacyclin, endothelium-dependent hyperpolarization (EDH) and thromboxane 
(TXA2) receptor in endothelium-dependent relaxation and contraction in the 
microcirculation of diabetic rats; secondly, to determine the expression of enzymes 
and receptors involved in mediating endothelial responses and finally to determine 
the early (2 weeks) and late changes (10 weeks) in the functional and molecular 
responses in the microcirculation of diabetes rats. This study consisted of four 
experimental groups; normal 2-week rats, diabetic 2-week rats, normal 10-week 
rats and diabetic 10-week rats (n=15 rats per group). Vascular function studies were 
performed using wire myography. The contributions of individual EDRF (NO, 
prostacyclin and EDH) and TXA2 receptor in mediating endothelium-dependent 
relaxations and contractions were evaluated in tail arteries of all the experimental 
groups. The expressions and distributions of endothelial nitric oxide synthase 




synthase (PGIS), prostacyclin (IP) receptor, TXA2 receptor and TXA2 synthase 
proteins were determined by Western blotting and immunohistochemistry. 
Endothelium-dependent relaxations were significantly decreased in diabetic 2-week 
[Rmax; 73.49 (11.04) % vs 89.32 (10.03) %, p=0.002] and diabetic 10-week rats 
[Rmax; 58.84 (18.79) % vs 89.32 (10.03) %, p<0.01], respectively compared with 
normal 2-week rats. NO-mediated relaxations were attenuated in diabetic 10-week 
rats compared with normal 2-week (p<0.001) and normal 10-week rats (p<0.001). 
EDH-mediated relaxations were lower in diabetic 10-week rats compared to normal 
2-week rats (p=0.012) and normal 10-week rats (p=0.017). Diminished relaxations 
to prostacyclin were seen in diabetic 10-week rats compared to normal 2-week 
(p<0.001) and diabetic 2-week rats (p=0.033). Western blotting and 
immunostaining showed that diabetes reduced expression of eNOS, IP receptor and 
PGIS proteins in rat tail arteries. For endothelium-mediated contractions, significant 
increase in endothelium-dependent contractions were seen in diabetic 10-week rats 
[Emax; 113.73 (51.32) % vs 34.80 (21.00) %, p<0.001], with a trend of increase in 
diabetic 2-week rats [Emax; 71.80 (46.02) % vs 34.80 (21.00) %, p<0.058] compared 
to normal 2-week rats. Significant increases in both COX-1 and COX-2 mediated 
contractions, and TXA2 receptor mediated contractions were seen in diabetic 10-
week rats. Trend of increased expression of COX-2 and TXA2 receptor proteins 
were observed in diabetic 10-week rats supporting the findings of functional 
studies. In conclusion, impairment in microvascular endothelium-dependent 
relaxations and increased endothelium-dependent contractions were observed in 
diabetic rats, and this worsened by prolonged diabetes. Therefore, early prevention 





CHAPTER 1  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Vasculature  
1.1.1 Introduction to vasculature and anatomy of the blood vessel wall 
The human circulatory system is a huge network of organs and vessels which 
is responsible for the distribution of blood, nutrients, hormones, oxygen and other 
gases to cells in the body. It is involved in the removal of waste products such as 
carbon dioxide from the cells. It also plays a prominent role in stabilizing body 
temperature and pH, and maintains homeostasis. The circulatory system is made up 
of three main independent systems that work together: the heart (cardiac); lungs 
(pulmonary); and vascular system consisting of arteries, veins, coronary and portal 
blood vessels. 
There are three major forms of blood vessels: artery, vein and capillary which 
differ in sizes and wall thickness. The arteries transport blood away from the heart 
while the capillaries facilitate the exchange of nutrients and gas between the blood 
and tissues. The blood is later transported back to the heart by the veins.  
Both arteries and veins exhibit similar structure except for the wall thickness: 
arterial wall is thicker, as they carry blood under a higher pressure. Capillaries are 
made up of a layer of endothelium and occasional connective tissue. The walls of 
arteries and veins are made up of three distinctive layers known as tunica intima 
(inner layer), tunica media (middle layer) and tunica adventitia (outer layer) [Figure 
1.1]. Tunica intima is lined by a mono layer of endothelial cells that surrounds the 
vascular lumen and comes in contact with blood flow. This layer is separated from 




made up by vascular smooth muscle cells (VSMC) and circularly arranged elastic 
fibre. This layer is separated from the outer layer by a thick elastic tissue called the 
external elastic lamina. The tunica adventitia, the outer layer is completely composed 
of connective tissue and is interlaced with nerve fibres that supply the blood vessel 
(nervi vasorum) and nutrient capillaries (vasa vasorum) in the larger blood vessels 
(Figure 1.2). 
As mentioned above, the core purpose of arteries is to supply body organs 
with blood. Due to the high pressure in the arteries, their walls are generally thicker 
than vein and as the blood flows to the organs, the arteries branches to smaller forms 
(Sandoo et al., 2010). Arteries can be classified into conducting arteries, conduit 
arteries and resistance arteries based on their location in the arterial tree (Figure 1.3). 
Conducting arteries are the largest arteries (aorta, pulmonary and carotid artery) 
(McEniery et al., 2007) in the body and have an enormous amount of elastic tissue 
that permits the vessel to expand and contract accordingly in response to ventricular 
contractions. These conducting arteries bifurcate into conduit arteries such as the 
brachial, radial and femoral arteries to direct blood to specific regions of the body 
(Pugsley and Tabrizchi, 2000). These conduit arteries further split to resistance 
arteries which are responsible for adequate perfusion of organ tissues and later 
distally form the microcirculation (Sandoo et al., 2010). 
The endothelial cell lining is present in all blood vessels, although the 
amount of connective tissue and smooth muscle vary according to the vessel's 
diameter and function. Therefore, endothelial cells are fundamental components that 
line the entire vascular system, from the heart to the smallest capillary, and play an 
important role in regulating the passage of materials (nutrients, gases, white blood 






























   












                                     
 
                             Figure 1.2 Histology of the blood vessels. 
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1.1.2 Microcirculation  
The microcirculation is described as small blood vessels of the vasculature 
that are embedded within the organs. These small vessels include small arteries, 
arterioles, capillaries, and venules (Levy et al., 2001; Levy et al., 2008).  According 
to Mulvany et al., 1990, small arteries with lumen diameter less than 500 µm are 
considered as microcirculation (Mulvany et al., 1990).   
 The main function of the microcirculation is to optimize nutrient and oxygen 
supply within the tissue where adequate perfusion is crucial for the integrity of tissue 
and organ function (Levy et al., 2001).   Furthermore, it is noted that at the level of 
the microcirculation, substantial drop in hydrostatic pressure occurs in the blood 
vessel. These arteries are known as resistance arteries and can easily adjust to the 
changes (vasodilation or vasoconstriction) in compliance to the metabolic needs of 
the tissues. Due to their ability in adapting to changes in local blood regulations, 
small arteries are extremely important in the regulation of overall peripheral 
resistance and responsible in controlling the systemic blood pressure (Christensen 
and Mulvany, 2001).  
Microvascular endothelial cells are one of the main targets for hyperglycemic 
damage, since the endothelial cells are unable to downregulate glucose transporter 
rate when the glucose concentration is high, thus causing intracellular hyperglycemia 
(Brownlee, 2005; Stehouwer, 2018). This causes microvascular endothelial 
dysfunction which is characterized by a decrease in nitric oxide (NO) availability, 
increased vascular permeability, increased leukocyte adhesion, and increased 
procoagulant activity (Brownlee, 2005; Stehouwer, 2018). Microvascular endothelial 




risk of developing cardiovascular complications such as coronary heart disease, 
cardiomyopathy, congestive heart failure; cerebrovascular and peripheral arterial 
disease (Rizzoni et al., 2003; Kalani, 2008; Lockhart et al., 2009). 
 Studying the microvasculature bed has become an area of interest ever since 
the microcirculation is reported to be the initial site for early manifestation of 
vasculopathy (Levy et al., 2001). Microvascular dysfunction takes place in multiple 
tissue beds long before the onset of atherosclerotic symptoms (Abularrage et al., 
2005). Impairment in the microvascular function is seen in patients with obesity (Al-
Tahami et al., 2011), diabetes mellitus (DM) (Caballero et al., 1999), hypertension 
(Levy et al., 2008) and renal diseases (Ramunni et al., 2009). 
 
1.1.3 The endothelium   
Endothelium is a simple squamous cell lining the entire circulatory system, 
from the heart to the smallest capillaries (Rajendran et al., 2013). Endothelial cells 
serve multiple purposes, though initially endothelium was considered to function as 
a barrier between the blood vessels and blood only (Galley and Webster, 2004; 
Rajendran et al., 2013).  
The discovery by Furchgott and Zawadzki in 1980 regarding the ability of 
endothelial to control vascular tone was a pioneering finding that leads to better 
understanding of endothelial functions beyond the barrier roles (Furchgott and 
Zawadzki, 1980).  Apart from its role as a regulator of vascular tone, the 
endothelium is also involved in multiple roles such as in modulation of platelet 
activation, leukocyte adhesion, and thrombosis.  It also functions in balancing the 
counter regulatory pathways which includes the control of vasomotion, cell 




Any disruptions to endothelial function lead to endothelial dysfunction (ED) 
which has been linked with cardiovascular disease progression. Exposure to 
cardiovascular risk factors such as tobacco use, physical inactivity, and obesity, 
increasing age, hypertension, hyperlipidemia and insulin resistance / hyperglycaemia 
can result in reversible or irreversible endothelial damage (Celermajer, 1997; 
Obrenovic-Kircanski, 2007). These harmful risk factors compromised the endothelial 
defence mechanism causing endothelial cell activation and dysfunction. 
Modifications in vasculature due to ED are linked to the pathogenesis of 
numerous diseases. One of the early signs of atherosclerosis is ED that occurs before 
morphological changes are visible in the vessel wall (Davignon and Ganz, 2004). ED 
plays a central role in the early pathophysiology of atherosclerosis in diabetes, 
hypertension and hyperlipidemia which are risk factors for cardiovascular disease 
(Park et al., 2001; Low Wang et al., 2016).  
 
1.1.3(a) Endothelium as a vascular tone regulator 
One of the most important roles of endothelium is to synthesize and secrete 
vasoactive substances that regulate vascular tone which contribute to vascular 
homeostasis.  Vasoactive substances released by endothelial cells can be divided into 
two types: endothelium-derived relaxing factors (EDRFs) and endothelium-derived 
contracting factors (EDCFs) (Furchgott and Vanhoutte, 1989).  EDRFs such as NO, 
prostacyclin (PGI2) and endothelium derived hyperpolarizing factor (EDH) cause 
blood vessels relaxation whereas EDCF such as endothelin I, angiotensin II and 
thromboxane A2 cause blood vessels contraction. 
Generally, a healthy and intact endothelium maintains the vessel environment 




damage to endothelial cells leads to disturbance in vascular homeostasis.  Damage to 
the endothelium disrupts the balance between vasodilators and vasoconstrictor and 
initiates the process of atherosclerosis that eventually leads to cardiovascular events 
(Davignon and Ganz, 2004).  
 
1.1.3(b) Endothelium-derived relaxing factors (EDRF) 
1.1.3(b)(i) Nitric oxide (NO)   
  
One of the most important vasodilator produced by the endothelium is NO 
(Palmer et al., 1988; Furchgott and Vanhoutte, 1989). It mediates endothelium-
dependent vasodilation by opposing the effects of endothelial contracting factors.  
NO is not only responsible for the vasodilatation which helps in blood 
pressure regulation (Moncada and Higgs, 1993), but also acts as anti-atherogenic 
substance. It impedes atherogenesis by inhibiting leukocyte and platelet activation, 
smooth muscle cell proliferation, oxidation of low density lipoproteins, synthesis of 
cytokines and platelet aggregation (Radomski et al., 1987; Hogg et al., 1995; Donald 
M. Lloyd-Jones and Kenneth D. Bloch, 1996; Rubbo et al., 2002; Levine et al., 
2012) 
Since NO plays a major role in vasodilation, diminished vasodilation is often 
related to the defect in NO production or activity. The reduced production of NO is 
mainly because of injury or damage to endothelial cells.  The impairment in NO 
production promotes atherosclerosis by causing vasoconstriction, platelet 
aggregation, smooth muscle cell proliferation and migration, leukocyte adhesion, and 
oxidative stress (Davignon and Ganz, 2004).  
NO is a soluble gas that is continuously synthesized by endothelial cells due 




2012). It is synthesized from the amino acid L-arginine by the enzymatic action of 
nitric oxide synthase (NOS) (Dimitris et al., 2012). Three different isoforms of NOs 
exist, that are endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) nitric 
oxide synthase, with each varying in structure and function. eNOS causes endothelial 
vasodilatation as it catalyses the oxidation of L-arginine resulting in the production 
of NO mainly, and L-citrulline as a by-product (Moncada and Higgs, 1993;Donald 
M. Lloyd-Jones and Kenneth D. Bloch, 1996). nNOS isoform acts as modulator of 
neuronal function which regulates synaptic neurotransmitter discharge (Prast and 
Philippu, 2001). Another isoform, iNOS is only expressed in cells that have been 
exposed to inflammatory conditions which activate the macrophages (Michel and 
Feron, 1997).  
The ability of blood vessels to relax depends on the activity of eNOS. eNOS 
is present in two forms: constitutive NOS (cNOS; type III) and inducible NOS 
(iNOS; type II). Under basal conditions, nitric oxide is primarily synthesized by 
cNOS which plays a major role in blood pressure regulation (Rees et al., 1989), 
whereas the production of NO from iNOS is very low. However during 
inflammation, the amount of NO produced by iNOS is greater than the amount 
produced by cNOS. The activity of iNOS is induced by immunological stimuli 
[bacterial endotoxins (e.g., lipopolysaccharide) and cytokines eg., tumor necrosis 
factor (TNF) and interleukins] and is Ca
2+  
independent (Schulz et al., 1992)  
Multiple cofactors such as reduced nicotinamide adenine dinucleotide 
phosphate (NADPH), flavine adenine dinucleotide (FAD), flavin mononucleotide 
(FMN), and tetrahydrobiopterin are also needed for NO production  
The NO production in the intact blood vessel is mostly obtained from the 




triggered to chemical stimuli (acetylcholine, bradykinin, adenosine triphosphate, 
thrombin, serotonin, histamine, insulin and substance P) or physical stimuli (shear 
stress, pulsatile stretching of the vascular wall and hypoxia) (Schmidt et al., 1992; 
(Donald M. Lloyd-Jones and Kenneth D. Bloch, 1996), where both works by 
increasing the calcium level.  Other vasoactive substances such as bradykinin can 
also trigger NO and the release other vasodilators (such as prostacyclin and EDH) 
resulting in the inhibition of platelet aggregation and blood vessels relaxation 
(Groves et al., 1995; Drexler, 1998).   
  The three NOS isoforms depend on the enzyme’s binding of the calcium 
regulatory protein calmodulin [CaM]. Both eNOS and nNOS are calcium dependent 
whereas iNOS is calcium independent and capable to bind with calmodulin even at 
low calcium level (Nathan and Xie, 1994; Michel and Feron, 1997).  
Inactive eNOS is bound to the protein caveolin which is located in small 
invaginations in the cell membrane called caveolae (Bucci et al., 2000; Sandoo et al., 
2010).  The stimulation from agonist or other stimuli invokes a local release of 
calcium which in turn causes eNOS to detach from caveolin (Bucci et al., 2000; 
Sandoo et al., 2010). The intracellular calcium attaches to the CaM in the cytoplasm 
of the cell, causes structural changes that allows it to bind to eNOS to get activated 
(Fleming and Busse, 1999; Sandoo et al., 2010). eNOS then converts L-arginine into 
NO (Palmer et al., 1988; Sandoo et al., 2010)  
The mechanism of NO production is entirely reliant on the levels of 
intracellular of Ca
2+
 in the endoplasmic reticulum and extracellular stores which 
diffuses into the cell. A reduction in Ca
2+
 causes the calcium-calmodulin complex to 
dissociate from eNOS, which in turn binds with caveolin and becomes inactivated 




As soon as NO is formed, it diffuses across the endothelial cell into the 
neighbouring smooth muscle where it binds to and activates the enzyme guanylyl 
cyclase (GC) (Ignarro et al., 1986). The GC mediates the conversion of guanosine 
triphosphate (GTP) to cGMP, which in turn induces smooth muscle relaxation via 
various mechanisms. cGMP is later hydrolysed back to GMP by a family of 
phosphodiesterase 5 (PDE5). 
cGMP stimulates protein kinase G (PKG) in order to activate myosin light 
chain phosphatase, the enzyme that dephosphorylates myosin light chains (MLC), 
preventing the MLC to bind to actin, thus preventing vasoconstriction and therefore 
promoting VSMC relaxation (Lee et al., 1997; Jones et al., 1999) .  




(BKCa) channels which are present in all tissues especially at the smooth muscle 
(Nelson and Quayle, 1995). Opening of BKCa channels hyperpolarizes the membrane 
and closes voltage-dependent Ca
2+
 channels, reduces Ca
2+
 influx, and decreases 
intracellular Ca
2+
 concentration which leads to VSMC relaxation (Fukao et al., 
1999).  
          Besides, PKG also can reduce the release of intracellular Ca
2+ 
in smooth 
muscle through the phosphorylation of both the IP3 receptor (IP3R) and the IP3R-
associated PKG-I substrate (IRAG). Phosphorylation of IRAG and IP3 receptor 
inhibits the release of calcium from the endoplasmic reticulum and thereby promotes 
vasorelaxation (Komalavilas and Lincoln, 1996; Münzel et al., 2003) 
Most of NO-mediated relaxation results from cGMP-dependent protein 
kinase activation, however NO can also directly activate SERCA and cause the 
removal of Ca
2+





cGMP also reduces Ca
2+
 release from the sarcoplasmic reticulum in the 
smooth muscle cell (Collins et al., 1986) and also helps to restore Ca
2+
 to the 






























Figure 1.4 Schematic illustration representing possible mechanisms of NO-
mediated relaxation in the blood vessel. Endothelial activation initiated by shear 
stress force or ACh lead to sudden rise in intracellular Ca
2+
 concentration causing 
NO generation. NO is made from L-arginine; this action is mediated by the 
endothelial nitric oxide synthase (eNOS).  NO later diffuses into VSMC triggering 
the activation of sGC, causing production of cGMP and PKG. PKG can causes 
relaxation via: a) the activation of myosin phosphatase which prevents the binding 
of myosin to actin, thereby inhibits the constriction process; b) phosphorylation of 
BKCa channels that hyperpolarize smooth muscle cells and cause the closure of L-
type Ca
2+
 channels, thus decreasing Ca
2+
 influx into VSMC; and c) phosphorylation 
of IRAG which reduced the release of Ca
2+
 from SERCA into VSMC cytosol. NO 
can also directly act on SERCA and assist the removal of Ca
2+
 from smooth muscle 
cytosol into the SERCA. 
 
BKCa, high conductance calcium activated potassium channel, CaM, calmodulin; 
IRAG, IP3R receptor associated PKG-I substrate, IP3R1, Inositol-1,4,5-
trophosphate receptor type-1; M, muscarinic receptor, MLC, myosin light chain 










1.1.3(b)(ii) Prostacyclin  
 
Another agent that contributes to vasorelaxation of blood vessels is 
prostacyclin (Moncada et al., 1976a). Both prostacyclin and NO are released by 
endothelial cells and their functions are relatively similar where they mainly prevent 
platelet aggregation and also cause vasodilatation (de Nucci et al., 1988; Mitchell et 
al., 2008) 
  Prostacyclin (also termed prostaglandin I2 or PGI2) is a member of the 
eicosanoid family of lipid molecules. Prostaglandin is produced via cyclooxygenase 
pathway which is also responsible for the production of thromboxane. These 
prostanoids, prostacyclin (PGI2) and thromboxane (TXA2) works antagonistically to 
maintain the homeostasis of vascular function (Vanhoutte and Tang, 2008). In 
contrast to prostacyclin, TXA2 promotes vasoconstriction and causes platelet 
aggregation. Under normal circumstances, prostacyclin opposes TXA2’s biological 
effects, however when the blood vessel is severely damaged, prostacyclin may 
reverse its action and cause vasoconstriction (Vanhoutte and Tang, 2008; Félétou et 
al., 2009). 
Prostacyclin is released from endothelial cells when triggered by hormonal 
stimuli. It is formed from the reaction of an intermediate arachidonic acid which is 
made from endothelial phospholipid or diaglycerol and catalysed by phospholipase 
A2 which is calcium-dependent (Mitchell and Warner, 1999). This arachidonic acid 
can either enter the cyclooxygenase (COX) pathway or the lipoxygenase pathway to 
produce prostacyclin, TXA2 or leukotriene respectively.  
There are two types of COX enzymes (COX-1 and COX-2) (Mitchell and 






and TXA2. Both isoforms are expressed differently in endothelial cells: COX-1 is 
typically expressed in normal endothelial cells while COX-2 is mainly expressed 
when damage occurs to endothelial cells; or when endothelial cells are exposed to 
inflammatory cytokines (Mitchell and Warner, 1999; Mitchell et al., 2006; Mitchell 
and Warner, 2006)  
      As mentioned above, prostacyclin is derived from arachidonic acid when 
catalysed by COX enzyme to form prostaglandin H2. Prostaglandin H2 acts as a 
precursor to produce other prostaglandins such as PGI2, PGD2, PGE2, PGF2 and 
TXA2 when they are catalysed by their respective enzyme synthases. Prostacyclin is 









Figure 1.5 Production of prostaglandins in endothelial cells.  Modified from Awtry 
and Loscalzo, 2000. 
5-HPETE,5-hydroperoxyeicosatetraenoic acid; COX-1, cyclooxygenase-1; COX-2, 
cyclooxygenase-2; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGF2; 
prostaglandin F2; PGI2 , Prostacyclin; ;PGD synthase, prostaglandin D synthase; 
PGE, prostaglandin E synthase; PGF, prostaglandin F synthase PGF, prostaglandin F 










As soon as prostacyclin is produced from the endothelium, it diffuses to 
VSMC to either cause vasodilatation or to nearby platelets to prevent platelet 
aggregation. In VSMC, prostacyclin binds to prostacyclin (IP) receptors on the cell 
surface, thereby initiating several processes that subsequently lead to vasodilation. 
Activation of IP receptors causes adenylyl cyclase to yield cyclic adenosine 
monophosphate which in turn activates protein kinase A (PKA). PKA causes the 
phosphorylation of the myosin light chain kinase (MLCK) to its inactive state and 
therefore prevents the binding of myosin to actin. PKA also decreases intracellular 
Ca
2+
 level which eventually leads to smooth muscle relaxation and vasodilation 
(Figure 1.6). Prostacyclin is a weak vasodilator and is rapidly broken down to 6-
keto-PGF1 and has half-life of approximately 42 seconds (Gryglewski, 2008; 















Figure 1.6 Prostacyclin productions by endothelial cells and vasodilation in vascular 
smooth muscle. Binding of ACh to muscarinic receptor causes sudden rise in 
intracellular Ca
2+
 concentration. This causes membrane phospholipid to form 
arachidonic acid which is then further catalysed to form prostaglandin H2 and 
prostacyclin. The released prostacyclin diffuses across the vascular smooth and binds 
to IP receptor (prostacyclin receptor) which in turn activates adenylyl cyclase to 
produce cAMP followed by activation of protein kinase A (PKA).  PKA causes 
reduction in calcium level and phosphorylation of the myosin light chain kinase 
(MLCK), which thwarts the binding of myosin to actin and therefore inhibits 
vasoconstriction leading to smooth muscle relaxation and vasodilation. It can be 
noted that PGI2 and TXA2 work as physiological antagonists. Modified from 
(Mokhtar and Rasool, 2015)  
AA, arachidonic acid; ACh, acetylcholine; COX-1, cyclooxygenase-1; COX-2, 
cyclooxygenase-2; EC, endothelial cells; IP, prostacyclin receptor; M, muscarinic 
receptor; MLCK, myosin light chain kinase; PGI2, prostacyclin; PGIS, prostacyclin 
synthase; PKA, protein kinase A; PL, phospholipids; PLA2, phospholipase A2 






1.1.3(b)(iii) Endothelium-dependent hyperpolarization factor  
 
Besides NO and prostacyclin, another candidate that cause vasorelaxation is 
identified as endothelial dependent hyperpolarization (EDH). EDH was initially 
described in the late 1970s, where the researchers suggested that this 
hyperpolarization might be due to NO. However, their suggestions went wrong 
where in 1988, a group of researcher proved that the endothelium-dependent 
vasorelaxation is not only contributed by NO and prostacyclin but also by EDH 
(Chen et al., 1988; Busse et al., 2002; Félétou and Vanhoutte Paul, 2006; Mokhtar 
and Rasool, 2015) 
There are two types of pathways which lead to EDH-mediated relaxation. 
One of the pathways is known as the classical EDH pathway. In this pathway, 
activation of endothelial cells is a prerequisite in order to begin the EDH response.  
Activation of endothelial cells by shear stress or agonist increases the intracellular 
calcium concentration where this event yields endothelial hyperpolarization 
opening of the small conductance calcium-activated potassium channels (SKCa) and 
intermediate conductance calcium-activated potassium channels (IKCa) (Félétou, 
2016; Garland and Dora, 2017; Goto et al., 2018; Murphy and Sandow, 2019). The 
importance of both potassium channels in mediating EDH response can be seen 
with the use of combined inhibitors such as apamin and charybdotoxin (or UCL 
1684 and TRAM-34; block SKCa and IKCa respectively) which inhibit this response 
(Zygmunt and Hogestatt, 1996; Andersson et al., 2000; Hinton and Langton, 2003).  
The use of combined blockers to SKCa and IKCa showed that both channels work 
via different pathways. The SKCa channel activates the inwardly-rectifying 









al., 2008). The opening of both channels causes outflow of K
+
 ions from the 
endothelial intracellular compartment which causes rapid increase of K
+
 in the 
myoendothelial spaces. Accumulation of extracellular K
+
 concentration causes 
hyperpolarization which subsequently leads to vascular smooth muscle relaxation 
(Dora Kim et al., 2008). Other than that, depending on the arteries and species 
studied, it is reported that EDH-mediated responses can be transferred via myo-
endothelial gap junctions (MEGJ). Electrical coupling that happened between 
endothelial cells and vascular smooth cells is directly transmitted where this 
response is mediated by MEGJ. This MEGJ protein functions as communication 
channels  between endothelial cells and surrounding VSMC (Sandow and Hill, 
2000; Heberlein et al., 2009; Félétou, 2016; Garland and Dora, 2017; Goto and 
Kitazono, 2019).                                                                                                                                                                                                                                                                                                                                                                                   
                The intracellular Ca
2+
 released from the endoplasmic reticulum (ER) is 
needed to initiate the EDH response, however recent studies revealed that the Ca
2+
 
influx through activation of transient receptor potential channels after ER calcium 
depletion also aids in the production of EDH via the downstream activation of SKCa 
and IKCa channels (Earley and Brayden, 2015; Garland and Dora, 2017; Grayson et 
al., 2017; Behringer and Hakim, 2019; Goto and Kitazono, 2019; Murphy and 
Sandow, 2019). 
Another type of pathway is known as the non-classical EDH pathway. In 
this pathway, hyperpolarization of vascular smooth muscle happens independently 
without the help of endothelial KCa channels. When then endothelial cells are 
triggered by ACh, diffusible factors such as NO, epoxyeicosatrienoic acids (EETs) 
and hydrogen peroxide (H2O2) are produced and transferred via internal elastic 




Miura et al., 1999; Campbell and Fleming, 2010; Edwards et al., 2010). This will 
lead to stimulation of different families of K
+ 
channels causing VSMC 
hyperpolarization. The hyperpolarization of VSMC reduce Ca
2+
 influx either by 
decreasing the opening probability of voltage-dependent calcium channels (CaV) or 
the CaV channel-dependent activation of the sarcoplasmic reticulum which will 















Figure 1.7 Endothelium-dependent hyperpolarization in the blood vessel.  In 
classical EDH-type responses, endothelial cells are triggered with agonist or shear 
stress which increases the intracellular calcium concentration due to calcium release 
from endoplasmic reticulum and calcium influx through the endothelial 
nonselective cation channels of the transient receptor potential (TRP) family. This 
in turn activate SKCa and IKCa channels which causes vascular hyperpolarization 




- ATPase and KIR channels respectively, or 
by means of direct transfer of electrical coupling through MEGJ. In non-classical 
EDH-type responses, presence of endothelium-derived diffusible factors such as 
NO, EETs and H2O2 leads to hyperpolarization of VSMC through activation of 
potassium channels. Adapted from Edwards et al., 2010. 
 
ACh, acetylcholine; IKCa, intermediate conductance calcium-activated potassium 
channels; KIR, inwardly-rectifying potassium channels; M, muscarinic receptor; 




-ATPase, sodium/potassium pump;  
SKCa, small conductance calcium-activated potassium channels; TRP, transient  











1.1.3(c) Endothelium contracting factors 
Shortly after the discovery of  NO and other members of endothelial relaxing 
factor, researchers explored the role of contracting factors in endothelial cells as it 
became obvious that despite the vasorelaxation role, under certain environments, 
endothelial cells cause contractions of the underlying vascular smooth muscle 
(Furchgott and Vanhoutte, 1989) 
There are many factors contributing to endothelium-dependent contraction. 
For instance, reduced production of NO or other vasodilators leads to prominent 
decrease in overall endothelial-dependent relaxation activity. Moreover, the 
production of vasoconstrictor products such as angiotensin II, endothelin-1 and 
products of arachidonic acid metabolism (endoperoxides, TXA2, and possibly 
isoprostanes) further augment contractions. These vasoconstrictors are also called 
endothelium derived contracting factors (EDCF) as they are directly involved in 
contractile activity of the VSMC. In addition, the sudden increase in oxygen-derived 
free radicals (superoxide anions) also intensifies endothelium-dependent 
contractions. The productions of EDCF are found greater in large vessels such as 
cerebral arteries and are further amplified with aging, spontaneous hypertension 











1.1.3(c)(i) Thromboxane (TXA2) as a vasoconstrictor 
 
        The involvement of thromboxane (TXA2) as a vasoconstrictor was initially seen 
while studying the heterogeneity in endothelium-dependent responsiveness in canine 
veins.  In canine veins, it was found that the mediators such as arachidonic acid and 
thrombin, which acts as endothelium relaxants in isolated arteries showed augmented 
contractions (De Mey and Vanhoutte, 1982). Similar observations were also obtained 
in other studies involving basilar artery of canine (Katusic et al., 1987; Katusic et al., 
1988).  Meanwhile, a study conducted in the aorta of spontaneously hypertensive rat 
(SHR) also reported that endothelium-dependent contraction is mediated by the 
product of COX (Luscher and Vanhoutte, 1986). Subsequent findings revealed that 
endothelium-dependent contractions are suppressed with the use of COX inhibitors 
proposing that down-stream products of cyclooxygenase enzyme (prostanoids) are 
responsible for endothelial contractions activity (Miller and Vanhoutte, 1985; 
Luscher and Vanhoutte, 1986; Yang et al., 2002; Yang et al., 2003; Wong and 
Vanhoutte, 2010). Most animal studies showed that endothelial contractions 
mediated by COX are augmented with aging (Koga et al., 1989; Mombouli and 
Vanhoutte, 1993; Shi et al., 2008), hypertension (Luscher and Vanhoutte, 1986; 
Auch-Schwelk et al., 1989; Koga et al., 1989; Yang et al., 2002; Tang et al., 2005), 
vasospasm (Dhein et al., 1989), and high glucose (Tesfamariam et al., 1990). 
Endothelium-dependent contraction is also considered to occur in humans as it was 
reported that in patients with essential hypertension; indomethacin (non-selective 
inhibitor of cyclooxygenases) practically normalizes the blunted vasodilator response 
to acetylcholine (Taddei et al., 1997). 
  As described previously, early manifestation of endothelial dysfunction is 




derived relaxing factors. This could be related to acute endothelial injury or due to 
the presence of diseases such as diabetes, hypertension and cardiovascular disease. 
Under these environments, when the endothelial cells are exposed to shear stress or 
agonists such as thrombin, acetyl choline (Boulanger et al., 1994), adenosine 
nucleotides (adenosine diphosphate and adenosine triphopspate) (Koga et al., 1989; 
Mombouli and Vanhoutte, 1993) or calcium ionophore (Katusic et al., 1988; Gluais 
et al., 2006b; Shi et al., 2007; Tang et al., 2007; Shi et al., 2008), the endothelial 
cells will produce more endothelial contracting factors which are mainly mediated 
by COX.   
Upon stimulation of endothelial cells, sudden calcium influx is seen.  This 
rapid accumulation of calcium originated either from sarcoplasmic reticulum release 
or from the activation of phospholipase C. An increase in calcium concentration is 
essential in causing endothelial contractions. For instance, when the extracellular 
calcium level is lowered (Okon et al., 2002), reduction in endothelial contraction is 
seen and is completely absent in another study (Wong Siu et al., 2009), whereas 
restoration of calcium ions is seen to normalise the endothelium contractions (Wong 
Siu et al., 2009). Many studies utilize calcium ionophore A23187 (calcium- 
increasing agent) since it directly permits entry of calcium ions across the membrane 
and therefore increases intracellular calcium levels and causes endothelial 
contractions (Okon et al., 2002; Shi et al., 2007; Tang et al., 2007; Vanhoutte Paul, 
2011). 
As mentioned previously, the calcium levels are increased when agonists 
such as acetyl choline or adenosine di- and triphosphate bind to specific receptors on 
the endothelial cells and causes phospholipase activation. Phospholipid activation is 




triggers the release of calcium from intracellular stores. This causes the decline in 
calcium levels intracellularly which in turn provokes calcium independent 
phospholipase A2 (iPLA2) to create more lysophospholipids (Tang et al., 2007; 
Wong et al., 2008; Vanhoutte Paul, 2011). The formed lyphospholipids opens the 
store-operated calcium channels and causes the inflow of extracellular calcium into 
the endothelial cells (Trepakova et al., 2001; Smani et al., 2004). This sudden 
outburst of cytosolic calcium ions will induce the calcium-dependent phospholipase 
A2 (cPLA2) to convert more membrane phospholipids into arachidonic acid (AA) 
(Wong and Vanhoutte, 2010; Vanhoutte Paul, 2011). AA can also be synthesized 
from DAG by diacylglycerol lipase (Hanna and Hafez, 2018). Depending on the 
need, the created AA will either enter COX or 5-lipoxygenase (5-LO) pathways to 
produce endoperoxides and leukocytes respectively.  
 In COX pathway, AA is converted to intermediate compounds, 
Prostaglandin G2 (PGG2) and then to Prostaglandin H2 (PGH2) which causes the 
production of  five bioactive prostanoids (PGE2, PGI2, PGD2, PGF2α) and TXA2 by 
tissue-specific synthases (Breyer et al., 2001; Funk, 2001). These prostanoids binds 
with their corresponding receptor located on smooth muscle (EP, FP, IP, TP, and 
DP) to produce biological actions. COX is seen as a rate-limiting enzyme and 
available in two isoforms, COX-1 and COX-2 (Garavito and DeWitt, 1999).  These 
isoforms are important in the synthesis of prostaglandin, however their expression, 
availability and distribution within the cells depends on the species and the blood 
vessel studied and also the health conditions of the donor (Furchgott and Vanhoutte, 
1989; Dalman and Porter, 1993; Tang and Vanhoutte, 2009; Vanhoutte, 2009; 
Vanhoutte et al., 2009; Wong Siu et al., 2009). Generally, COX-1 is highly 




vessels. However COX-2 is seen highly induced in the case of inflammation, aging, 
hypertension, diabetes and renal injury (Wong and Vanhoutte, 2010; Li et al., 2018). 
Among the product of cyclooxygenase, TXA2 appears to evoke endothelial 
contractions. The formed TXA2 readily diffuses to vascular smooth muscle and binds 
to TXA2 receptor resulting in the increase of intracellular calcium level, activation of 
Rho kinase pathway and eventually contractions (Chan et al., 2009; Wong and 
Vanhoutte, 2010). Binding to TXA2 receptors triggers the calcium release from 
sarcoplasmic reticulum. The calcium increase enhances the binding of Ca
2+
 to 
calmodulin (CaM) which in turn activates myosin light chain kinase (MLCK) to 
phosphorylate the myosin light chain (MLC) of myosin II. The degree of MLC 
phosphorylation controls the extent to which VSMC contracts: MLC 
phosphorylation causes VSMC contraction while MLC dephosphorylation causes 
VSMC relaxation. The Rho-kinase pathway controls the degree of phosphorylation 
of the myosin light chain of myosin II, mostly via inhibition of myosin phosphatase, 
and subsequent Ca
2+
 sensitization (Fukata et al., 2001).  In many experimental 
studies, the release of TXA2 is seen amplified  where incubating the vessels with 
TXA2 antagonist abolish the  endothelial contractions (Auch-Schwelk et al., 1990; 
Huang et al., 2004; Vanhoutte Paul, 2011) 
Other than TXA2, PGH2 which acts as an intermediate compound in TXA2 
production is also seen to exhibit contraction (Ge et al., 1995; Gluais et al., 2006a; 
Gluais et al., 2007; Tang and Vanhoutte, 2008a; Wong and Vanhoutte, 2010) by 
activating TXA2 receptors of vascular smooth muscle (Auch-Schwelk et al., 1990; 
Kato et al., 1990; Ge et al., 1995; Wong and Vanhoutte, 2010). Moreover, PGH2 
together with prostacyclin become the main reservoir for EDCF. Prostacyclin plays a 




relaxation (Moncada et al., 1976b; Zou et al., 2002; Hink et al., 2003; Gluais et al., 
2005). Instead of producing relaxation, prostacyclin appeared to cause endothelial 
contractions, though the expression of IP receptors is seen unaltered (Levy, 1980; 
Gluais et al., 2005; Tang and Vanhoutte, 2008a; Liu et al., 2012). This 
unresponsiveness of IP receptors might start a positive feedback on the endothelial 
cells, resulting in abundant overexpression of PGI2 synthase with the major release 
of PGI2 by endothelial cells provoked by acetylcholine or calcium ionophore 
A23187. Expression of PGI synthase is also seen greatly augmented with aging and 
spontaneous hypertension in aortic endothelial cells of the rat (Numaguchi et al., 
1999; Tang and Vanhoutte, 2008a; Vanhoutte Paul, 2011). Due to lack of 
responsiveness of IP receptors, prostacyclin binds to TXA2 receptors and thus 
produces the contractions (Gluais et al., 2005; Vanhoutte Paul, 2011).  
In addition, TXA2 receptor is also seen as a villain as it permits 
endoperoxides at higher concentrations to bind to it and thereby mediates 
vasocontraction (Feletou et al., 2010). Generally, endoperoxides are unstable 
however they are seen to activate thromboxane receptor (TXA2 receptors) or known 
as TXA2 receptor of VSMC (Ito et al., 1991; Asano et al., 1994; Ge et al., 1995). For 
example, greater releases of endoperoxides are seen in the aorta of the SHR than in 
that of normotensive rats (Ge et al., 1995; Ge et al., 1999; Vanhoutte Paul, 2011). 
The role of endoperoxides in mediating contraction become more significant when 
the activity of PGI2 synthase is reduced due to the local production of peroxynitrite 
(Zou et al., 1999; Zou et al., 2002; Gluais et al., 2005) as this diverts arachidonic 
acid toward PGE2 and PGF2 synthases (Gryglewski et al., 1986; Zou et al., 1999; 
Zou et al., 2002; Gluais et al., 2005) to produce more of the endoperoxides and 





Figure 1.8 Endothelium-dependent contractions due to the production of prostanoids 
and ROS. Adapted from (Wong and Vanhoutte, 2010). 
The endothelial contraction is initiated with sudden accumulation of intracellular 
Ca
2+
. This increase is generated by receptor-dependent agonists, such as 
acetylcholine or ADP, or imitated with calcium increasing agents, such as the 
calcium ionophore A23187. This results in depletion of calcium which dislocates the 
inhibitory calmodulin (CaM) from iPLA2. Triggered iPLA2 produces 
lysophospholipids (LysoPL) which open store-operated calcium channels (SOCs) 
resulting entry of extracellular calcium into the endothelial cells. This sudden 
outburst of calcium ions activates cPLA2, which causes the production of 
arachidonic acids (AA). The produced AA is then converted to prostanoids catalysed 
by cyclooxygenase-1 (COX-1). The produced prostanoids eventually binds to TP 
receptors which in turn increase Ca
2+ 
levels. Binding to TP receptor activates 
increase in Ca
2+
 release from the sarcoplasmic reticulum. Intracellular increase in 
calcium levels enhances the binding of Ca
2+
 to calmodulin (CaM). This complex 
activates myosin light chain kinase (MLCK) to phosphorylate the myosin light chain 
(MLC) of myosin II. The Rho-kinase pathway modulates the level of 




myosin phosphatase, and contributes to agonist-induced Ca
2+
-sensitization in smooth 
muscle contraction.  
AA=arachidonic acid; ACh=acetycholine; ADP=adenosine diphosphate; cPLA2, 
calcium dependent phospholipase A2; COX, cyclooxygenase; iPLA2, calcium 
independent phospholipase;m=muscarinic receptors; P=purinergic receptors; 
PGD2=prostaglandin D2; PGE2=prostaglandin E2; PGF2α=prostaglandin F2α; 
PGI2=prostacyclin; PLA2=phospholipase A2; ROS=reactive oxygen species; TXA2= 





















1.2 Diabetes mellitus  
1.2.1 Introduction to Diabetes Mellitus 
Diabetes mellitus (DM) is one of the oldest diseases known to humankind as 
the early evidence of the symptoms had been documented on papyrus scrolls by 
ancient Egyptians about 3500 years ago (King and Rubin, 2003).  This metabolic 
disease is characterized by the manifestation of high glucose level in blood, a 
condition called hyperglycemia. The presence of hyperglycemia results from 
defectiveness in insulin secretion, impaired insulin action, or both (American 
Diabetes Association, 2009).  
1.2.2 Prevalence of diabetes 
Diabetes mellitus becomes a major threat as the numbers of patients keep 
expanding yearly.  Based from World Health Organization (WHO) report, it was 
estimated that 108 million adults were living with diabetes and this figure went 
up to 422 million adults in 2014. The prevalence among adults over 18 years of 
age has also increased from 4.7% in 1980 to 8.5% in 2014.  WHO also reported 
that the largest numbers of people with diabetes were from South-East Asia and 
Western Pacific regions contributing nearly half diabetes cases in the world 
(WHO,2016). This figure is expected to double in the future as it is closely 
associated with our non- healthy life styles which include dietary habits and lack 
of physical activity.  
Patients with diabetes have a shorter life expectancy. The average life 
span of a 50-year-old individual with diabetes is 6 years shorter than those 
without diabetes (Seshasai et al., 2011). Reports by WHO showed that in 2012, 
diabetes alone has been the cause for 1.5 million deaths. It also contributed to an 




other diseases. WHO also predicted that diabetes will be the seventh leading 
cause of death in 2030 (WHO, 2016).  
According to the National Health and Morbidity Survey (NHMS) 2019 by 
the Ministry of Health (MOH), the prevalence rate of diabetes in adults has increased 
in Malaysia from 13.4 per cent in 2015 to 18.3 per cent in 2019, with diabetes 
defined as having sugar levels 7.0 mmol/L or above. The data also showed that an 
estimated 3.9 million adults in Malaysia aged 18 and above had diabetes as of last 
year, higher than 3.5 million in 2015. This rise is a concern as the National Health 
and Morbidity Survey in 2019 revealed that almost one in five Malaysian adults 
suffered diabetes. The NHMS 2019 survey revealed that 49 per cent of people with 
diabetes had never been examined or diagnosed with the chronic disease (National 
Health and Morbidity, 2019).  These statistics revealed that females, older age group, 
Indians, and urban residents were at the highest risk of DM. 
 
1.2.3 Aetiology of diabetes mellitus 
Diabetes mellitus (DM) is a chronic disease that happens when our body 
failed to produce enough insulin or fail to use insulin. The presence of diabetes is 
characterised by high glucose level in the blood. Insulin, a hormone produced by 
beta cells of the pancreas normally regulates blood glucose level in the body. 
Insulin allows the transport of glucose from the bloodstream to the cells where it 
is consumed as a source of energy. This hormone along with glucagon help to 
keep the blood glucose level from getting too high (hyperglycemia) or too low 
(hypoglycaemia). The normal fasting glucose level in our body is between 3.9 




There are three major forms of diabetes mellitus: diabetes mellitus type 1, 
diabetes mellitus type 2 and gestational diabetes mellitus (Triplitt et al., 2015). Type 
1 diabetes is autoimmune diseases where the insulin producing cells are destroyed by 
the body own immune system.  Formerly this type of diabetes is known as insulin-
dependent diabetes since the patients require daily administration of insulin due to 
the total insulin deficiency in the body. Type 1 diabetes is generally diagnosed 
during juvenile and adolescence which contributes for 5-10% of newly diagnosed 
diabetes.  The cause of type 1 diabetes is unknown, however the researchers 
postulated that genetic and environmental factors played a role in the development of 
this disease (Aathira and Jain, 2014; Triplitt et al., 2015). Type 1 diabetes is more 
severe compared to type 2 diabetes. Hypoglycaemia is reported to be a significant 
cause of morbidity and mortality in type 1 diabetes (Kyi et al., 2015). 
Type 2 diabetes contributes 85 to 95 percent of all diagnosed diabetes cases. 
The defect in insulin secretion or insulin resistance contributes to the development of 
type 2 diabetes. Decline in insulin secretion occurs when there is a gradual drop in 
pancreatic beta-cell function, and also reduced beta-cell mass, which is manifested 
before the onset of type 2 diabetes (Pratley and Weyer, 2001; Stumvoll et al., 2005; 
Pratley, 2013; Triplitt et al., 2015).  Several data also suggested that by the time of 
diagnosis, a mere 20% of beta-cell function remains (DeFronzo et al., 2010).  The 
progress of chronic hyperglycemia additionally causes more damage to beta-cell 
function and insulin secretion (Pratley, 2013). Despite different aetiologies involved, 
all type 2 diabetes patients share abnormalities in carbohydrate, fat and protein 
metabolism (American Diabetes Association, 2009).  
Gestational diabetes is first detected during pregnancy. It occurs in about 5% 




(Ben‐Haroush et al., 2004; Kampmann et al., 2015). Gestational diabetes not only 
affects the mother but also the child. The mother is exposed to the risk of caesarean 
and operative vaginal delivery whereas in the new-born have increased risk for 
macrosomia, shoulder dystocia, neonatal hypoglycemia and hyperbilirubinemia 
(Catalano and Ehrenberg, 2006). Women with GDM are also at  high risk of getting 
type 2 diabetes mellitus (T2DM) later in life; their children are also prone to develop 
diabetes type 2 and obesity early in life (HAPO Study , 2008). 
 
1.2.4 Diabetes and microvascular complication  
  In the long run, the exposure to high blood glucose leads to other 
consequences such as microvascular and macrovascular complications. 
Microvascular complications include small blood vessel diseases such as diabetic 
retinopathy, diabetic neuropathy and diabetic nephropathy. Macrovascular 
complications occur in larger blood vessels such as in heart, brain and peripheral 
tissue which eventually causes coronary artery disease, stroke and peripheral 
vascular disease. These complications lead to early morbidity and mortality among 
diabetic patients (IDF, 2019). For example, diabetic retinopathy is one of the most 
frequent causes of impaired vision or blindness among adults aged 20-74 years 
(Fong et al., 2003).  Diabetes nephropathy causes chronic kidney disease and if left 
untreated, leads to end stage kidney disease which accounts for 20-40 % of all 
diabetic cases (Gheith et al., 2016).  Diabetic neuropathy, another type of 
microvascular complications involves both peripheral and autonomic nerves that 
predispose the risk for foot ulcers and limb amputation where it affects about 50% of 




risk of amputations, approximately 25 times greater compared to non-diabetics 
(Boulton et al., 2005). 
 
1.2.5 Diabetes and atherosclerosis 
Diabetic patients with microvascular complications generally have higher 
tendency of accelerated atherosclerosis which can cause cerebrovascular and 
cardiovascular diseases and premature death (Kalofoutis et al., 2007).  
Atherosclerosis is referred as hardening of arteries due to plaque formation.  
This plaque formation consists of fatty substances, cholesterol, cellular waste 
products, calcium and other substances. The formation of plaque at specific sites will 
further cause intimal inflammation, necrosis, fibrosis, and calcification where 
overtime, the accumulation of plaques narrows the opening of lumen and thus 
reduces blood flow and oxygen supply which may abruptly cause macrovascular 
disease such as coronary heart disease, ischemic stroke, and peripheral vascular 














1.3 RATIONALE OF THE STUDY  
The number of diabetes cases in Malaysia is escalating with statistics in 2019 
showing that 3.6 million Malaysians out of 32 million having diabetes. Out of the 3.6 
million diabetic patients, 1.78 million were women. These figures are worrisome as 
this figure is expected to increase yearly together with many unreported diabetic 
cases. It was estimated that about 1.8 million Malaysians have diabetes, but is 
unaware of it as they do not go for the screening (National Health and Morbidity, 
2019). 
Diabetes leads to microvasculopathy which contributes to cardiovascular 
complications such as heart diseases, nephropathy, neuropathy and retinopathy. 
Endothelial dysfunction (ED), defined as impaired endothelial mediated relaxation is 
the initial pathology leading to atherosclerosis and vasculopathy in diabetes. 
Endothelial cells line the inner blood vessel and releases endothelial derived factors 
(EDF) such as endothelial derived relaxing factors (EDRF) that dilate blood vessels 
and endothelial contracting factors (EDCF) which constrict blood vessels. In larger 
vessels, imbalance in the availability of EDCF and EDRF has been reported to lead 
to ED. However, little is known in the diabetic microcirculation especially diabetics 
with peripheral artery disease (PAD). A few studies had previously reported on 
alterations in EDRF in the microcirculation of diabetic rats. However, no studies had 
addressed the roles and alterations caused by EDCF in the microcirculation of 
diabetic rats. No studies had reported on the effects of early and late diabetes on 
microvascular endothelial derived relaxing & contracting factors. In this study, the 
contribution of cyclooxygenase enzyme (which includes COX-1 and COX-2) and 
thromboxane (TXA2) receptor in endothelium-mediated contraction were 




(NO), endothelium derived hyperpolarizing factors (EDH)] and thromboxane 
(TXA2) receptor in early (2 weeks) and also late phases of diabetes (10 weeks) were 
also studied in streptozotocin induced diabetic rats.  
This study methodology consists of two parts. The first part consists of in-
vitro functional vascular response studies which assessed the contributions of each 
EDRF (NO, EDH and prostacyclin) to endothelium-mediated relaxation in the 
microcirculation of two and ten weeks diabetic and normal rats. The contribution of 
TXA2 receptor to endothelium-dependent contraction and the enzymes responsible 
for TXA2 production (COX-1 and COX-2) were also evaluated in normal and 
diabetic vessels. This method involved a series of experiments where microvessels 
were incubated with different pharmacological blockers that inhibit the synthesis or 
action of these factors.  
The second part consists of molecular studies (western blot and 
immunohistochemistry) to determine presence and protein expression of the 
enzymes and receptors involved in the synthesis and action of these EDRF and 
TXA2. Alterations in enzymes and receptors involved during the early (2 weeks 
diabetes) and late phases of diabetes (10 weeks diabetes) were studied.  
In this study, tail artery of rats were studied as it was reported that the 
microcirculation of tail artery of the rats are similar to distal blood circulation of  
human limbs and digits in terms of the anatomy and reactivity profile (Wu et al., 
1995; Fang and Galiano, 2008; Spradley et al., 2013). Distal blood circulation 
includes the microcirculation of the lower limbs. Besides, the tail artery of the rat has 
also been employed as an assay tissue to assess the impairment of vascular function 





Previous studies showed that diabetes patients with peripheral arterial disease 
(PAD) are at high risk of developing morbidity and mortality from cardiovascular 
diseases. PAD also is identified as a significant risk factor for diabetic foot diseases 
which contributes to foot amputation (American Diabetes Association, 2003, 
Prompers et al., 2008; Chen et al., 2015). Diabetic patients with PAD also 
demonstrated severe impairment in endothelial function (Marso and Hiatt, 2006; 
Kiani et al., 2013). From this current study, we will have better insights on the 
mechanisms leading to the development of ED that might aid in the early 
management of diabetes patients particularly those with peripheral arterial disease. 
Findings from this study could be beneficial to improvise targeted therapeutic 
strategies and also introduce pharmacological intervention in the management of 


















The general objectives of this study are: 
1. To determine the early and late changes in endothelium-dependent relaxation 
and contraction responses in the microcirculation of diabetic rats 
The specific objectives of this study are: 
1. To determine the contribution of NO, prostacyclin, EDH and TXA2 receptor  
in endothelium-dependent relaxation and endothelium-dependent contraction 
in the microcirculation of diabetic rats  
2. To determine the expression of enzymes (eNOS, PGIS, COX-1, COX-2 and 
thromboxane synthase) and receptors (IP receptor and thromboxane receptor) 
in mediating the endothelial relaxing and contracting responses in the 
microcirculation of diabetic rats. 
3. To determine the early (2 weeks) and late (10 weeks) changes in the 
functional study evaluating endothelial dilators (NO, prostacyclin and EDH) 
and endothelial prostanoids (COX-1, COX-2 and TXA2 receptor) together 












 MATERIALS AND METHODS 
 
2.1 Study Design 
This study was conducted in 120 Sprague-Dawley rats with each body weight 
ranged from 250 to 350 grams and age between 10 to 12 weeks.  In this study, 
endothelium-mediated contraction and relaxation of microcirculation was evaluated 
during early and late state of diabetes (two and ten weeks duration, respectively). 
The vascular responses in diabetic rats were compared with the responses in normal 
rats. In this study, rats were divided into 4 groups: (1) normal 2-weeks rats (2) 
diabetic 2-week rats (3) normal 10-week rats and (4) diabetic 10-week rats (Figure 
2.0).  
Previous studies reported that endothelial dysfunction started at to occur as 
early as one (Zhang et al., 2012) or two weeks after diabetic induction (Rodríguez-
Mañas et al., 2003). However not all the studies agreed with that conclusion (Brands 
et al., 1994; Pieper, 1999; Nacci et al., 2009). Therefore in this study we choose 
duration of 2 weeks to evaluate microvascular endothelial function. Literatures also 
showed that diabetic complications such as neuropathy, nephropathy and retinopathy 
started to be observed after 8-14 weeks of diabetic induction (Suh, 1999; Parkar N 
and Addepalli V, 2014; Si et al., 2014; Taskıran et al., 2016; Lee et al., 2017; 
Peterson et al., 2017). Generally microvascular complication due to diabetic 
manifested at the late stage of diabetes therefore the duration of 10 weeks chosen for 







2.1.1 Ethical approval  
  Animal study was approved by the Animal Ethics Committee of USM, 
Health Campus, Kubang Kerian, Kelantan (Appendix A). 
 
2.1.2 Sample size calculation 
 The principal parameter of interest used in this study was percentage of 
maximum relaxation induced by acetylcholine (ACh). Two means equation with 
two-tailed alpha (α) set at 0.05 with power of 90% were applied. The mean 
difference of interest (14.24%) and standard deviation (11.78) from control rats 
were taken from previous findings Mokhtar et al., 2016. 
The calculation for the sample size is shown below: 
Calculation of sample size. 
n = 2 (Zα +Zβ) ² SD²/d² 
n = 2 (1.96+ 1. 28) ² (11.78)²/ (14.24)² 
n = 15 (for each group) 
Where n is defined as a sample size of each group 
Zα = 1.96 for α set at 0.05 (two-tailed) 
Zβ = 1.28 for β set at 90% 
SD = standard deviation, 11.78 
d = estimated smallest difference of significance, 14.24 
Therefore, a minimum number of 15 rats required for each group to complete this 
study. 
2.1.3 Animal handling and care 
  A total of one hundred and twenty healthy rats were received from the 




acclimatize to the surrounding condition a week before starting the study.  
Throughout the study period, the rats were caged in polypropylene cages in a well-
ventilated room with room temperature of 25 ± 2°C and exposure to 12 hours light/ 
12 hours of dark cycle. The rats had unrestricted access to tap water and rat pellets 





         Figure 2.0 Study flow chart 
DM was induced using STZ 
intraperitoneally (60 mg/kg in citrate 
buffer). DM was confirmed after 72 
hours of STZ induction. Rats with 
FBG > 12mmol/dl were considered 
diabetes  
 













2.1.4 Diabetes induction and confirmation 
The rats in this study were divided into two groups; normal and diabetic group. Each 
group consisted of 60 rats. Normal rats were treated with sodium citrate buffer 
(0.1M) via intraperitoneal injection, while streptozotocin (STZ) was used to induce 
diabetes in the experimental rats. Prior to diabetes induction; the rats were fasted for 
12-16 hours. The dosage of STZ used to induce diabetes in each rats were calculated 
based on their body weights. The fasted rats were later intraperitoneally injected with 
a single dose of STZ (60 mg/kg dissolved in sodium citrate buffer, 0.1 M, pH 4.5). 
Following the administration of STZ, the rats were monitored carefully for 72 hours. 
The presence of STZ causes the pancreas to lose its function that is by damaging 
Langerhans islet beta cells and thus induces experimental diabetes. To confirm the 
successful induction of diabetes in the experimental rats, blood from the tail tip was 
drawn after 72 hours of diabetes induction by tail pricking method. The blood 
glucose level was measured using the Accu-Check glucometer for continuous two 
days to ensure that the rats were diabetic. The rats with the fasting blood glucose 
readings higher than 12 mmol/dl were considered diabetic (Mokhtar et al., 2016). 
Once the rats developed diabetes, random blood glucose levels were checked weekly 
until the end of study to ensure that rats were kept under diabetic condition.  Other 
symptoms such as weight loss, increased in urination (polyuria), increased in 
appetite (polyphagia), thirsty (polydipsia) were also noted in diabetic rats.  
 
2.1.4(a) Measurement of other parameters 
Measurements of body weight for control and diabetic rats were also taken 




water and food were also regularly monitored as the diabetic required more water 
and rat pellets. 
2.1.4(b) Preparation of sodium citrate buffer (0.1 M, pH 4.5) 
Streptozotocin which was measured according to rat’s body weight was later 
diluted in sodium citrate buffer. To prepare 0.1 M sodium citrate buffer, 1.4705 g of 
tri-sodium citrate was dissolved in 50 ml double distilled water and the pH was 
adjusted to 4.5 with 2 M HCl. 
2.1.4(c) Euthanization of rats 
 At week two, total numbers of 60 rats (30 rats from normal groups and 30 rats 
from diabetic groups) were sacrificed with pentobarbitone sodium (70 mg/kg, given 
intraperitoneally). The same procedure was repeated at week ten where rats from 
normal groups (n=30) and diabetic group (n=30) were sacrificed. The rat tail was 
dissected and kept in physiological saline solution (PSS) to be used in functional 
and molecular experimentation. 
2.1.4(d) Tissue collection and dissection 
 The tail part of the rats was used in this study. The artery from the tail was 
preferred due to its subcutaneous localization and it reflects better view of 
peripheral arteries (Mokhtar et al., 2016). The tail part can be divided into 
proximal, middle and distal segments with each part differing in diameters. The 
distal part of the artery (smallest in internal diameter, 286–315 μm) was selected for 
functional study while arteries from middle and proximal were used in Western 




 In this study, to evaluate the endothelium-mediated contraction and 
relaxation responses, the experiments were done separately since the functional 
experiment required long hours and this causes the non-viability of the vessels.  
After the confirmation of DM [72 hours after induction with STZ), the rats 
were killed at 2 weeks and 10 weeks. At week two, to study the role of endothelium-
derived relaxing factors, thirty rats from normal groups (n=15) and diabetic groups 
(n=15) were sacrificed. Another thirty rats were also sacrificed at week two and used 
to evaluate endothelium-mediated contracting response. The proximal and middle 
part of the tail arteries were kept for molecular studies. The same procedure repeated 
at week 10 where another sixty rats were sacrificed to evaluate endothelium-



























Figure 2.1 Diagram of transverse sections of rat tail pointing the dorsal vein, lateral 

















2.2 Functional Study (Wire Myography) 
In this in vitro procedure, the vascular reactivity at second (2
nd
) and tenth 
(10
th
) weeks of diabetes was evaluated. This experiment was carried out using dual 
wire myograph which was developed by Mulvany and Halpern to investigate active 
and passive properties of the vessels with the diameters between 100 and 1000 µm 
(Mulvany and Aalkjaer, 1990) 
Functional study using wire myograph consist of few steps such as 
preparation of resistance arteries, mounting of the vessels, the normalization 
procedure, assessment of tissue viability, and the response of vascular function 
towards drugs with the presence of pharmacological inhibitors (Spiers and 
Padmanabhan, 2005).  
In this study, we used dual wire myograph (410A), DanishMyo (DMT) 
Technology, Denmark which is designed to test responsiveness of two different 
small vessels (30 μm - 3 mm) simultaneously. This instrument also comes together 
with Powerlab 20, ADInstruments, Denmark where this instrument acquires tension 
data from the myograph in real time, which is displayed, recorded and analyzed 
using LabChart Pro software (Figure 2.2). It also consists of an internal heating 








            
 
 













2.2.1 Preparations of vessels for functional study 
The procedure used in this study was done based on previous study (Mokhtar 
et al., 2016). Once the vessels were isolated from the tail, the vessels were placed on 
petri dish filled with physiological saline solution. With the aids of micro dissecting 
scissors and forceps, the vessels were cleaned from the fats and connective tissues. 
The vessels were then cut into rings (2 mm in length). To study the endothelium- 
independent responses, the endothelial cell layers were removed by rubbing the 
lumen of the artery with human hair.  
 
2.2.2 Preparation of buffers 
(a) Physiological Saline Solution (PSS) 
Physiological saline solution was prepared freshly before starting the experiment. 
This solution acts as internal buffer that maintains the same physiological 
conditions of the vessels as they exist in their normal body. To create similar 
environments, the physiological saline solution aerated with carbogen (95% oxygen 
and 5% carbon dioxide) for 20 minutes until the pH of the solution reached 7.4 and 
the experiment were conducted at 37 °C.  To make physiological saline solution, all 
the chemicals listed below (Table 2.1) were weighed accordingly and dissolved in 








              
 
 Table 2.1. Recipe of the physiological saline solution 
Chemicals Molecular weight (g/mol) Conc.(mmol/l) Conc.(g/l) Manufacturers 
Sodium Chloride (NaCl) 58.44 118.99 6.954 Merck, Germany 
Potassium Chloride (KCl) 74.56 4.69 0.35 Merck, Germany 
Magnesium sulfate heptahydrate 
(MgSO4-7H2O) 
246.48 1.17 0.29 Merck, Germany 
Potassium dihydrogen phosphate 
(KH2PO4) 
136.09 1.18 0.16 
 
Merck, Germany 
Sodium hydrogen carbonate 
(NaHCO3) 
84.01 25.00 2.10 Merck, Germany 
Glucose 198.77 5.50 1.09 Merck, Germany 
Calcium chloride dehydrate 
(CaCl2-2H2O) 




2.2.3 Mounting of the vessels  
Before mounting the vessel in the myograph chamber, the chambers were filled 
with physiological saline solution with the heater (set to 37ºC) and gas (O2) turned 
on.  While waiting the temperature of the chamber to stabilize, the 2 mm of vessels 
placed in the petri dish was prepared to be cannulated under the microscope.  By 
using the forceps, the vessel on the petri dish was gently threaded with first 
tungsten wire (40 μm diameter). The vessel was then moved to the chamber and 
placed at the myograph jaw which was attached to micrometer (Figure 2.3a). The 
wire was then placed in the center and was clamped by adjusting the micrometer 
(Figure 2.3b). Using the screwdriver, both end of the wires were wrapped under the 
screw of the jaw and tighten up (Figure 2.3c). Once the first wire fixed, the second 
wire was gently push into the lumen artery on top of the first wire (Figure 2.3d). 
The wire was introduced in one movement in order to avoid endothelial damage to 
the vessel. The jaws were moved gently to clamp the wire. The far end of the 
second wire was tied to the screw of the jaw which was attached to transducer 
(Figure 2.3e).  Without damaging the mounted vessels, the jaws were opened 
slightly apart and the wires were adjusted parallel. The set-up of this experiment 
(two wires with one secured to micrometer and another to isometric force 
transducer) allows the wall forces produced by the vessel to be measured as it is 
held between the wires (Figure 2.4) (Bevan and Osher, 1972; Mulvany and 









Figure 2.3 Mounting protocol of the artery; (a) the artery was placed in the middle 
of the jaw (b) the micrometre was adjusted to clamp the wire. (c) the end of the 
wires was secured tightly under the screw (d) the jaw was parted slightly before 
inserting the second wire on top of the first (e) the jaw was then closed before tying 
























2.2.4 Normalization of vessel lumen 
Before proceeding to the normalization, the mounted vessels were washed 
three times with PSS solution. The vessels were then allowed to equilibrate for 
thirty minutes.   
The initial validation study on normalization procedure was conducted by 
(Mulvany and Halpern, 1977). From this study, it showed that the best experimental 
conditions were attained if one defines the vessel size as being the size when the 
vessel is fully relaxed and under a transmural pressure of 100 mmHg 
(internal circumference). Therefore in this study, the size of the vessel is first 
determined at a given transmural pressure (the pressure between the two sides of a 
vessel: internal – external wall pressure) and then set to the pressure at which 
contraction is optimal. According to Mulvany’s group, the internal circumference 
of the vessel was determined at a standard target transmural pressure of 100 mmHg 
(IC100=13.3 kPa), with the vessel relaxed. The size of the vessel that was optimal 














2.2.5 Wire Myograph  protocol 
2.2.5(a) Chemical used in smooth muscle viability and endothelial functions  
              test 
  
Table 2.2 showed the chemicals used in smooth muscle and endothelial function 
tests in wire myograph. Phenylephrine (PE) and acetylcholine (ACh) were freshly 
prepared each time the experiment conducted.  Both drugs were diluted according 
to the desired concentrations with PSS (the final concentrations required for each 
drugs were determined in our preliminary study). Potassium chloride (KCl) were 
prepared and stored in room temperature. To check the smooth muscle function, 60 
mM KCl (equivalent to 100 μl) was taken from the bottle and used. This 
concentration was determined from our previous study methodology (Mokhtar et 
al., 2016).  
  
Table 2.2 List of chemicals used in smooth muscle and endothelial function tests. 
Chemicals  Molecular Weight Manufacturers 
Potassium Chloride (KCl) 74.56 Merck, Germany 
Acetylcholine chloride (ACh) 181.66 Sigma Aldrich, USA. 











2.2.5(b) Smooth muscle viability test (Contractile function) 
 
After the normalization, the vessels were left to equilibrate for one hour. Then the 
vessels were treated with KCl. This causes vascular smooth muscle to depolarize, 
increase in inflow of extracellular Ca
2+
 and thus activates the contraction process. 
This step is conducted to confirm whether the function of VSMC remains intact as 
the vessels might be damage during the isolation or when the mounting task was 
carried out. KCl (60mM) was added into the chamber to observe for the contractile 
activity. The vessels were exposed to KCl for 10 minutes or until contractile 
activities became stable. The chamber was then washed with physiological saline 
solution until the vessels were allowed to relax to baseline. After 10 minutes, the 
vessels were then exposed to repeated dose of KCl. The vessels that failed to 
response to 60 mM of KCl were discarded. 
 
2.2.5(c) Endothelium function test 
 
This step is carried out to check the ability of the vessels to relax where 
endothelium can be easily damaged while mounting or dissecting. Besides that, this 
step is also needed to double check whether the endothelial cells were successfully 
removed in the case of studying endothelium-independent responses.  
To check the endothelial viability function, the vessels was tested with a 
standard vasoconstrictor, phenylephrine (PE) and endothelium-dependent 
vasodilator, ACh. Phenylephrine causes contraction by acting on α1-adrenergic 
receptor of endothelial cells whereas ACh mediates endothelial relaxation by 




release of nitric oxide or other relaxing factors from the endothelium and the ability 
of endothelium to relax  
In this study, PE (10
-4
 M) was added to the chamber until contraction was 
stable. The concentration of PE was decided based from our initial observation 
where optimal contraction produced. From our initial observation when the wrong 
concentration of PE used, the arteries exhibited limited ability to maintain 
constriction. The mean tension to phenylephrine must reach 80% to that of KCl 
contraction. Once the PE contraction remained plateau, ACh (10
-4
 M) was 
introduced into the chamber so that vessels were able to relax. The vessels with 
intact endothelium were seen fully relaxed when introduced with ACh. The vessels 
in both chambers were washed and allowed to relax for 15 minutes before 

















2.2.6 Endothelium-dependent relaxation 
2.2.6(a) Pharmacological inhibitors used for endothelium-dependent relaxation 
study 
Table 2.3 listed type of inhibitors used in this protocol. Stock solutions were 
prepared in their respective solvents. The stock solutions were stored at -20°C 
freezer. They were freshly diluted to the appropriate concentrations with control 
solution before the experiment. The final concentration in the chamber for each drug 
was based on previous experience in the laboratory or studies reported in the 






















Chemical names Alternative name  Molecular weight Manufacturer 
1-[(2-Chlorophenyl) diphenylmethyl]-1H-pyrazole  TRAM 34 344.84 Tocris Bioscience, UK 
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic 
acid 
Indomethacin 357.8 Cayman, USA 
6,10-diaza-3(1,3)8,(1,4)-dibenzena-1,5(1,4)-diquinolinacy 
clodecaphane 
UCL 1684 654.44 Tocris Bioscience, UK 
L-NG-Nitroarginine methyl ester hydrochloride   L-NAME 269.7 Cayman, USA 






Table 2.3.1  Inhibitors used in endothelium-dependent relaxation study 
Inhibitors       Actions  Diluents Final 
concentration 
 in chamber 
Reference 
Indomethacin  Non-selective inhibitor of cyclooxygenase (COX) 




 ( 50μl) 
(Luksha et al., 2004; 
Mokhtar et al., 2016) 
L-NAME  Inhibitor of NO synthase  and  hinders NO 
Productions 
Distilled water  10
-4
 M 
 ( 50μl) 
(Georgescu et al., 2011; 
Mokhtar et al., 2016) 
KCl   Opening of K+ channels in the vascular smooth muscle 
cells abolished EDH activity. 
Distilled water 30 mM 
( 50μl) 
(Shimokawa et al., 1996) 
TRAM 34  Blocker of intermediate calcium-activated potassium 




 M  
( 50μl) 
(Leo et al., 2011; 
Mokhtar et al., 2014; 
Mokhtar et al., 2016) 
UCL 1684 
 
 Blocker of small calcium-activated potassium channels 




 ( 50μl) 
(Leo et al., 2011 
(Mokhtar et al., 2014; 





2.2.6(b) Protocol of endothelium-dependent relaxation 
Endothelium-dependent relaxations were investigated in pre-contracted 
artery. The purpose of this protocol was to find out the contribution of NO, 
prostacyclin and EDH in microvasculature of diabetic and normal rats at two and ten 
of the experiments.   
Four vessels from four groups (diabetic 2-week rats, normal 2-week rats, 
diabetic 10-week and normal 10-week rats) that passed the viability and presence of 
endothelium tests were selected and treated under the following conditions: 
a) Control solution: The vessels were not incubated with any inhibitors, and 
pre-contracted with PE (10
-4






b) NO-mediated relaxation: The vessels were incubated for 30 minutes with the 
combination of indomethacin (10
-5
 M, non-selective inhibitor of COX that 





M) and KCl 30 mM (to inhibit EDH activity). After the 
incubation, the vessels were pre-constricted with PE (10
-4
 M) and exposed to 




 M ACh) 
c) EDH-mediated relaxation: The vessels were incubated with L-NAME [10-4 
M, inhibitor of eNOS] and indomethacin (10
-5
 M) for 30 minutes. The 
vessels were then pre-contracted with PE (10
-4
 M) and exposed to cumulative 




 M ACh) 
d) Prostacyclin-mediated relaxation: The vessels were incubated with L-NAME 
[10
-4










minutes. The vessels were then pre-contracted with PE (10
-4
 M) and exposed 




 M ACh) 
 
Table 2.3.2 showed the procedure involved in endothelium relaxation study in rat 
arteries. Figure 2.5 showed illustration of myograph tracing and formula to 


















Table 2.3.2 Procedures of endothelium-dependent relaxation study in rat arteries  








Normalization (pre-stretching of an intact vessel) 
Smooth muscle viability test (Contractile function) 
- 2X exposure to KCl 60 mM  
 
Endothelial function test 
- Pre contracted with phenylephrine ( 10-4 M) 
- ACh (1 x 10-4  M) 
 













 KCl 30 mM 




 LNAME(10-4 M) 
 TRAM34(10-6 M) 
 UCL1684(10-6 M) 
 KCl 30mM 
Pre-constriction Phenylephrine(10
-4


















Figure 2.5 : Diagram of myograph tracing and calculation procedures for the 
percentage of relaxation. 
 
mN 
Time (ml.n ute) 30 :·00 
a 
a = Baseline 
b = Maximal contraction to phenylephrine 
cl = Relaxation at dose cl 
c2 = Relaxation at dose c2 
c3 = Relaxation at dose c3 
b-a = Acrual contract ion to phenyiephrine 
c 1-b = Acrual relaxat ion at dose c I 
c2-b = Acrual relaxat ion at dose c2 
c3-b = Acrual relaxat ion at dose c3 
Perc entage of relaxation for dose cl 
= [(cl-b) / (b-a)] x 100 
Perc entage of relaxation for dose c2 
= [(c2-b) / (b-a)] x 100 
Perc entage of relaxation for dose c3 




2.2.7 Endothelium-independent relaxations 
2.2.7(a) Chemical used to study the endothelium-independent relaxations  
Table 2.4 listed the drugs used to study the endothelium-independent relaxations. 
The phenylephrine (PE) and sodium nitroprusside dehydrate (SNP) were freshly 
prepared and diluted with physiological saline solution (PSS) before the study. All 
the drugs were diluted to the appropriate concentrations with PSS solution before the 
experiment. The final concentration needed for the study was taken according to the 



















Table 2.4 List of chemicals used in endothelium-independent relaxation. 
 
 
Table 2.4.1: Characteristic of the drugs used in endothelium-independent relaxation. 
 
 
Chemicals  Molecular Weight Manufacturers 
Phenylephrine (PE)      203.67 Sigma Aldrich, Germany 
Sodium Nitroprusside dehydrate       297.95 Sigma Aldrich, Poland 
Drugs Actions  Diluent Final concentration in 
chamber 
Reference 
PE  α-1 adrenoreceptor agonist  Distilled water  10-
4
 M Preliminaries study 









2.2.7(b) Protocol of endothelium-independent relaxation 
To determine the endothelium-independent relaxations, the endothelium 
needs to be removed first. Therefore the purpose of this experiment is to check the 
relaxation of vascular smooth muscle without the involvement of endothelium. The 
endothelial cells were removed by rubbing the intimal surface of the lumen with a 
human hair (Kirkby et al., 2012). Prior to conducting endothelium-independent 
tests, the absence of endothelial cells was confirmed by lack of relaxation caused by 
ACh agonist. The vessels with relaxation less than 30% were selected for 
endothelium-independent relaxation test. The selected vessels without endothelium 
were pre-contracted with PE and their responds towards cumulative concentration 
of SNP were tested.  
Table 2.4.2 showed the procedure involved in endothelium- independent 
relaxation study in rat arteries. The calculation for endothelium-independent test 















      








 Normalization (pre-stretching of an intact vessel) 
Smooth muscle viability test (Contractile function) 
- 2X exposure to KCl 60 mM 
Endothelium function test 
- Pre contracted with phenylephrine (10-4 M) 
 ACh (10
-4















2.2.8 Endothelium-dependent contractions 
2.2.8(a) Pharmacological inhibitors used in endothelium-dependent 
contractions  study 
Table 2.5 listed the type of inhibitors used in this protocol. Stock solutions were 
prepared in their respective solvents. The stock solutions were stored in a -20°C. 
They were freshly diluted to the appropriate concentrations with control solution 
before the experiment. The final concentration in the chamber for each drug was 


































Indomethacin 357.8 Cayman, USA 
2-Valeryloxybenzoic acid  Valeryl 
salicyclate 














Calimycin  Calcium 
ionophore  
A23187 




L-NG-Nitroarginine methyl ester 
hydrochloride   











Table 2.5.1  Inhibitors used in endothelium-dependent contractions study 
Drugs       Actions  Diluents Final concentration 














Indomethacin  Non-selective inhibitor of cyclooxygenase (COX) 





(Okon et al., 
2002; de 
Sotomayor et 

















 Optimize EDCF- mediated response 













(Tang et al., 
2005) 
(Okon et al., 
2002) 
(Qu et al., 2010) 
 
 

















(Zhang et al., 
2004; Gluais et 
al., 2005; de 
Sotomayor et 
al., 2007; Shi et 
al., 2008) 
(Tang et al., 
2005) 





(Gluais et al., 
2007; Tang and 
Vanhoutte, 
2008b) 






(Gluais et al., 








2.2.8(b) Protocol of endothelium-dependent contractions 
  
Endothelium-dependent contractions were studied in quiescent artery (artery 
with endothelium). The purpose of this protocol was to find out the roles of 
cyclooxygenase enzymes (COX-1 and COX-2), and thromboxane receptor (TXA2 
receptor) in endothelium-mediated contraction of the microvasculature in normal and 
diabetic rats at two and ten of the experiments.   
All the vessels were incubated with L-NAME (10
-4
M), an NOS inhibitor, to 
optimize endothelium-dependent, COX-dependent contraction. Contractions to the 
calcium ionophore, A23187 (receptor independent activation) were studied under the 
following environments: 
1. In control solution: the vessels were incubated with L-NAME for 30 minutes 




M). This step was to determine whether endothelium-dependent 
contractions occur in small arteries of the rat tail and were there alterations in 
the presence of diabetes. 
2. In the presence of indomethacin: the vessels were incubated with L-NAME 
and indomethacin (10
-5
 M) for 30 minutes and then subjected to cumulative 




M). This step was to 
determine whether endothelium-dependent contraction was mediated by 
products of cyclooxygenase. 
3. In the presence of valeryl salicylate: the vessels were incubated with L-
NAME and valeryl salicyclate (3 x 10
-3
 M, an inhibitor of COX-1) for 30 








M). This step was to determine if COX-1 plays a role 
in the contraction.  
4.  In the presence of NS398: The vessels were incubated with L-NAME and 
NS-398 (10
-6
 M, an inhibitor of COX-2) for 30 minute and then subjected to 




M). This step 
was to determine if COX-2 plays a role in the contraction.  
5.  In the presence of S18886: The vessels were incubated with the TXA2 
receptor antagonist, S18886 (10
-7 
M) and L-NAME for 30 minute and then 




M). This step was to determine whether the endothelium-dependent 
contractions of small arteries of the rat tail involves activation of TXA2 
receptors on the vascular smooth muscle 
 
Figure 2.6 showed illustration of myograph tracing and formula to calculate 
percentage of contraction induced by calcium ionophore. Increases in tension were 






























I= Baseline for I ' 1 KCI 
2= 1 d maximal coltt.raction to KCl 
3= Baseline for 2•• KCI 
l- 1 EMa.=l -1 
J } 12'· m_- 4-3 4= 2•d maximal contract ion to KQ 
) = .l::laseline 
a-5= Total Contraction at do;e a 
b-5=Total Contraction at do!e b 
c-5- Tulal Cou tt·ac tiun at <.lose .,; 
d-5=Total Contnction at dosed 






Average KC!. contraction 
PercentaGe of contraction at dose a : [a- 51 (Average KCI ·contract ion)] >< 100 llo 
Percentage of contraction at dose b : [b- 51 (Average KCi contraction)] x 100 % 
Percentage of contraction at dos.e c : [ c- 51 (Average KCI contract ion)] x I 00 llo 
Percemage of conrraction at dose d : [d - 5/ (Average KCi comract ion)] x 100 % 




2.3 Western blotting 
2.3.1 Introduction to western blot 
In this method, a mixture of proteins is parted according to their molecular weight, 
transferred to solid support or membrane and the target proteins were marked using 
primary and secondary antibody for the detection. We studied the expression of 
cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2), thromboxane receptor 
(TXA2 receptor), thromboxane synthase (TXA2 synthase), endothelial synthase 
(eNOs), prostacyclin receptor (IP receptor) and prostacyclin synthase (PGIS). The 
expressions of these proteins were then compared between normal and diabetic rats, 
and between 2 and 10 weeks diabetes. 
 
2.3.2 Materials 
Table 2.6, 2.6.1 and 2.6.2 listed the instruments, antibodies and chemicals and 















Table 2.6 List of instruments used in Western blotting 
Instruments Manufacturers  
Ice-maker AF 200 Scotsman 
Image analyser  Vilber Lourmat Fusion FX7-826 
France 
Mini Protean B cells BioRad, USA 
NanoDrop 1000 UV- Vis Spectrophotometer  Thermo Fisher Scientific, USA 
PowerPac Basic BioRad, USA 
Refrigerated Centrifuge Hettich Zentrifugen, Tokyo 
Scanner  
Spectrophotometer Thermoelectron Corporation, UK 
Trans-blot SD Semidry transfer cell BioRad, USA 
Vortex mixer IKA 
 









Type of antibodies Manufacturers 
Anti β-actin antibody Abcam, UK 
Anti-Cyclooxygenase 1 antibody Abcam, UK 
Anti-Cyclooxygenase 2 antibody Abcam, UK 
Anti- Prostaglandin I synthase antibody Abcam, UK 
Anti-Thromboxane A2 receptor antibody Abcam, UK 
Anti-Thromboxane A2 synthase antibody Abcam, UK 
Donkey anti-goat IgG (HRP) GeneTex,  Taiwan  
Goat Anti- Rabbit IgG H&L (HRP) Abcam, UK 
IP Receptor (Prostaglandin II receptor) Santa Cruz Biotechnology, INC 
NOS3 antibody  
[endothelial nitric oxide synthase, eNOS] 




Table 2.6.2 List of chemicals and consumables used in Western blotting 
Chemicals/Consumables Molecular weight Manufacturer 
2-Mercaptoethanol 78.13 Merck, Germany 
30% acrylamide/bis  Bio-Rad Laboratories. Inc, 
CA 
Ammonium persulfate 228.20 Biorad Laboratory Inc., 
USA 
Bovine serum albumin  Amresco,Ohio 
Bromophenol blue  669.96 Sigma Aldrich, Austria 
Chemiluminescent HRP substrate  Nacalai Tesque, Japan 
Glycerol 92.1 Calbiochem, CA 
Glycine 75.6 Merck, Germany 
Immobilon-P, PVDF membrane - Millipore Corporation, 
USA 
Methanol  32.04 Ajax Firechem, Australia 
Phosphate buffer saline tablet  Sigma Aldrich, USA 
Prestained broad range protein 
marker ladder (5 to 245 kDa) 
 SMOBIO, U.S.A 
RIPA lysis buffer with protease 
inhibitor 
- Sigma Aldrich, USA 
Skimmed milk powder - Anlene 
Sodium Chloride 58.44 Merck, Germany 
Sodium dodecyl sulfate (SDS) 288.38 Biorad Laboratory Inc., 
USA 
TEMED - Sigma Aldrich, USA 
Trizma Base 121.1 Sigma Chemical Co., USA 
Trizma hydrochloride 157.6 Sigma Chemical Co., USA 














2.3.3 Buffers for SDS PAGE electrophoresis and Western blotting 
a) 0.5 M Tris- Base pH 6.8 
To prepare Tris- base with the concentration of 0.5 Molar, 6.06 g of Tris- base were 
weighed and dissolved in 70 ml distilled water. The pH of the buffer was then 
adjusted to 6.8 with HCl. The solution was then refill up to 100 ml and was stored 
at 4°C. 
b) 1.5 M Tris Base pH 8.8 
To prepare 1.5 M Tris base, 90.86 gram of Tris- base was dissolved in 250 ml of 
double distilled water and the pH was adjusted to 8.8. The buffer was top up with 
double distilled water to reach final volume of 500 ml and was stored at room 
temperature 
c) Ammonium persulfate (10%) 
To make ammonium persulfate (10%) freshly, 0.1 g of ammonium persulfate was 
dissolved in one ml of distilled water.  
 d) Blocking buffer (5%) 
Milk was used as blocking buffer: to prepare 5% of it, five gram of non-fat dry milk 
powder, Anlene was dissolved in 100 ml phosphate buffer saline (PBS). This buffer 
was made freshly each time before the use 
e) Coomassie blue solution 
To prepare Coomassie blue stock solutions, 0.8 g of Coomassie blue powder was 
dissolved in 100 mL of methanol which were then added with 260 ml of distilled 
water. Before the usage, the 90 mL of stock solution were added with 10 mL of 






f) Destaining solution 
The solution was prepared by mixing 400 mL of methanol with 100 mL of acetic 
acid and 500 mL of distilled water.  
g) Phosphate buffered saline/Tween-20 (PBS-T) 
PBS was bought readily from Sigma Aldrich, USA. To prepare one litre of PBS, 
about five tablets were dissolved in one litre of distilled water.  
PBST was prepared by adding one ml of Tween-20 to 1000 ml of PBS. This PBST 
solution was then used as washing buffer and to dilute the antibody.  
h) Ponceau S solution 
The solution was prepared by dissolving 0.2 g of Ponceau red with 1 mL of acetic 
acid. The solution was then made up to 100 mL with the addition of double distilled 
water.  
i) Reducing sample buffer/ Laemmli buffer 
 Sample buffer was prepared by adding 0.76 g of Tris-base, one g of SDS and 10 ml 
of glycerol in 30 ml double distilled water and the pH was adjusted to 6.8. Prior to 
use, 10% 2-mercaptoethanol and 0.05% bromophenol blue were added to the 
buffer. 
j) Running buffer 
Running buffer was prepared by dissolving three g of Tri-base, 14.4 g of glycine 
and one g of SDS in 800 ml double distilled water and the pH was adjusted to 8.3. 
The buffer was top up with double distilled water to reach final volume 1000 ml 
and was stored at 4 °C. 
k) Sodium dodecyl sulfate (SDS) 
10% of SDS was prepared by dissolving 10 g of SDS powder to 80 ml of distilled 




l) Stacking buffer   
Stacking buffer was prepared by dissolving 6 g of Tri-base and 0.4 g of sodium 
dodecyl sulfate (SDS) in 70 ml double distilled water and the pH was adjusted to 
6.8. The buffer was top up with double distilled water to reach final volume of 1000 
ml and was stored at 4 °C. 
m) Transfer buffer 
Transfer buffer was prepared by dissolving 3 g of Tri-base, 14.4 g of glycine and 
0.37 g of SDS in 800 ml double distilled water and followed by the addition of 200 





















2.3.4 Tissue lysate preparation 
The proximal and distal part of tail arteries were harvested and placed in 
centrifuged tube containing one hundred microliter of ice-cold RIPA buffer. By 
using the micro scissors, the tissues were crushed into small pieces so that the 
tissues were completely lysed and released the protein of interest. The homogenized 
sample lysate was let to incubate for 10 minutes at 4 °C before the lysate was 
centrifuged at 12 000 rpm for 20 minutes at 4 °C.  The supernatant of the lysate was 
collected and were stored in deep freezer (-80 °C). The remaining tissues were 
discarded. 
2.3.5 Protein assay quantification 
The prepared samples contain unknown protein concentration. The amount of the 
protein presence in the samples were determined by using NanoDrop 1000 UV- Vis 
Spectrophotometer (Thermo Fisher Scientific, USA) at 280nm absorbance . This 
step is to ensure equal loading of protein in gels electrophoresis. Two microliter of 
the sample was placed on top of the pedestal. The absorbance value of the protein 
was detected by the internal spectrometer of NanoDrop.  
2.3.6 Preparation of gel for gel electrophoresis 
The protein molecules were parted according to their molecular weight by SDS-
PAGE. To begin the electrophoresis process, two separate gels (4% stacking gel 
and 8.0 % resolving gel) were prepared freshly. This method is known as Laemmli 
(Laemmli, 1970). The glass plates were washed and wiped with 70% ethanol before 
assembling it onto casting stand. The short plates were laid on top of bigger plates 
and the plates were clamped together. Distilled water was applied onto it to check 
whether it was tightly sealed and no leakage. The water was then discarded. The 




2.6.3.  The resolving gel was poured into the plates until one particular level 
(briefly leaving behind 2 cm from the top so that the comb was inserted later).  
Distilled water was then added on top of resolving gel and the gel was let to 
polymerize. The water was then discarded once the gel was polymerized. Similarly, 
the stacking gel was prepared (recipe in the table 2.6.3) and was added on top of 
resolving gel and the comb were inserted. The gel was let to harden. After the gel 
was harden, the comb was carefully removed and the wells were cleaned with 
distilled to remove the acrylamide debris. The gel was then detached from the 
casting stand and transferred to the electrophoresis tank containing running buffer.  
 
 
2.3.6(a) Sample preparation 
Prior to loading the samples in the well of the gel, the samples needed to be boiled. 
We used 80 µg of samples where the volume of the samples to be added was 
calculated from the protein quantification method (2.3.5). The calculated samples 
Table 2.6.3 Recipe of stacking and resolving gel preparations 
Chemicals  Volume 
Stacking gel (4%)  
30% acrylamide/bis 0.53 ml 
0.5 M Tris Base 1ml 
Double distilled water 2.4 ml 
Ammonium persulfate 40 µl 
SDS 40 µl 
TEMED 4 µl 
Resolving gel (8%)  
30% acrylamide/bis 2.67 ml 
1.5 M Tris Base 2.5 ml 









were pre-mixed with sample buffer in an equal ratio before boiling at 95˚C for 5 
minutes. The volume of the sample to be added to the gel to get 100 µg of protein 
was determined from the protein assay quantification method. 
 
2.3.6(b)SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
About five microliter of the protein ladder (5 kDA to 245 kDA) was loaded to first 
lane of the well. The boiled samples were added into other empty wells.  The black 
lead of electrophoresis tank was connected to the negative terminal and the red lead 
to the positive terminal of power lab. The gel was run at 120 V until the dye reached 
the bottom of the gel. The gel was then subjected to protein blotting immediately.  
 
2.3.7 Semi dry protein transfer 
Before transferring the protein onto the PVDF membrane, the membrane was 
activated with methanol for few minutes before treating them in transfer buffer for 
10-15 minutes.  The gel was removed from the electrophoresis tank and also from 
the glass plates before washing it with distilled water. The gel was then equilibrated 
in transfer buffer for 10-15 minutes. The filter pads were also wetted with the 
transfer buffer. The filter pads were then assembled on top of transblot which served 
as an anode followed by the PVDF membrane, gel and finally the filter paper. Air 
bubbles were removed by rolling the falcon centrifuge tube on top of each layer. 
This sandwich type arrangement was then covered with the cathode plate and the 
transfer was performed at 18 V for 2 hours 30 minutes. The membrane was stained 
with Ponceau S solution to ensure the efficiency of the transfer. The gel was also 






2.3.8 Antibody incubation and detections 
The membrane was blocked for one hour at room temperature in blocking PBS 
buffer containing 5% non-fat dry milk and 0.1% Tween 20. Membrane was then 
incubated with the corresponding primary antibodies in blocking buffer. The detail 
of dilution factor and duration of antibodies incubation were listed in the Table 
2.6.4. After being washed three times with washing PBS buffer containing 0.1% 
Tween 20 (PBS-T) for 5 minutes, the membrane was incubated for one hour with 
polyclonal secondary antibody which was horse-radish peroxidase (HRP)-
conjugated in blocking buffer. Membrane was then washed three times prior to 
detection by Chemi-Lumi One Super. Image analysis was performed using Image 
Analyser (Vilber Lourmat Fusion FX7-826 France). The intensity of protein bands 
representing the amount of proteins was measured with Image J software 
(http://rsb.info.nih.gov/ij/). The relative protein presence of eNOS, COX-1, COX-2, 
PGIS or IP receptors was expressed as the total amount of protein (indicated by the 














Table 2.6.4 Dilution and duration of incubation for antibodies used in Western 
blotting  
Antibody Western blotting 
Dilution Incubation 
Duration 
Anti β-actin antibody 1:5000 Overnight 
Anti-Cyclooxygenase 1 antibody 1:2 000 2 hours 
Anti-Cyclooxygenase 2 antibody 1:2 000 2 hours 
Anti-Prostaglandin I synthase antibody 1:2 000 2 hours 
Anti-Thromboxane A2 receptor antibody 1:2000 2 hours 
Anti-Thromboxane A2 synthase antibody 1:2000 2 hours 
Donkey anti-goat IgG (HRP) 1:2000 1 hours 
Goat polyclonal secondary antibody to 
rabbit IgG-H&L (HRP) 
1:2000 1 hours 
IP Receptor (Prostaglandin II receptor)            1:2000 Overnight 





















In this study, immunohistochemistry (IHC) methods were applied to detect the 
presence and locations of selected proteins in tissue sections. The distribution and 
locations of COX-1, COX-2, TXA2 receptor, TXA2 synthase, eNOs, PGIS and IP 
receptor were performed in four different groups of rats [normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats  and diabetic 10-week rats] . 
2.4.1. Materials  
Table 2.7, 2.7.1 and 2.7.2 refer to the instruments, chemicals and consumables used 
during immunohistochemistry. 
 


















Instruments  Manufacturers 
Cold plate Thermoelectron Corporation, USA 
Hot plate  Thermoelectron Corporation, USA 
Light microscope with image analyser Olympus Corp., Japan 
Microtome, Shandon 325 Thermoelectron Corporation, USA 
Tissue embedding centre Thermoelectron Corporation, USA 
Tissue floatation bath, HI 1210 Leica, Solms, Germany 




Table 2.7.1 List of antibodies used in IHC 
 







Type of antibodies Manufacturers 
Anti-Cyclooxygenase 1 antibody Abcam, UK 
Anti-Cyclooxygenase 2 antibody Abcam, UK 
Anti- Prostaglandin I synthase antibody Abcam, UK 
Anti-Thromboxane A2 receptor antibody Abcam, UK 
Anti-Thromboxane A2 synthase antibody Abcam, UK 
Donkey anti-goat IgG (HRP) GeneTex,  Taiwan  
Goat Anti- Rabbit IgG H&L (HRP) Abcam, UK 
IP Receptor (Prostaglandin II receptor) Santa Cruz Biotechnology, INC 
NOS3 antibody[endothelial nitric oxide synthase, 
eNOS] 
Santa Cruz Biotechnology, INC  
Chemicals/ Reagents  Molecular weight Manufacturers 
Acetic acid 60.05 J.T. Baker, PA,USA 
Ammonia solution 25% 17.03 Merck 
Ethanol absolute 46.07 HmbG Chemicals, Germany 
Formaldehyde 30.03 Mallinckrodt chemicals 
St.Louis, MO, USA 
Hydrogen peroxide (30%) 34.01 J.T. Baker 
Mounting DPX  Invitrogen, MA, USA 
Sodium Chloride 58.44 Merck 
Stable Diaminobenzidine (DAB)  Invitrogen, USA 
Trisodium citrate dehydrate 294.10  
Trizma hydrochloride 157.6 Sigma Aldrich 
Tween-20 1228 Sigma Aldrich 




2.4.2 Recipe of the buffers 
a. Preparations of blocking solutions (5%) 
 5% of blocking buffer was prepared by dissolving five gram of milk powder in 100 
ml of TBST. This solution was freshly prepared each time before the experiment. 
b. Preparations of ethanol (95%) 
The solution was prepared by adding 950 ml of pure ethanol (100%) into 50 ml of 
double distilled water. 
c. Preparations of ethanol (80%) 
Eighty percent of pure ethanol was prepared by mixing 800 ml of pure ethanol 
(100%) with 200 ml of double distilled water. 
d. Preparations of Ethanol (70%) 
Seventy percent of pure ethanol was prepared by adding 700 ml of pure ethanol 
(100%) with 300 ml of double distilled water. 
e. Preparations of Ethanol (50%) 
Fifty percent of pure ethanol was prepared by equally adding 500 ml of pure ethanol 
(100%) with 500 ml of double distilled water. 
f. Preparations of Hydrogen peroxide, 3% 
Ten millilitre of 30% hydrogen peroxide solution was diluted in 90 ml double 
distilled water to obtain 100 ml of 3% hydrogen peroxide 
g. 10 mM Sodium citrate buffer, 0.05% Tween-20, pH 6.0 
 10 mM sodium citrate buffer was prepared by dissolving 2.94g of tri- sodium citrate 
dehydrate in 1000ml of distilled water. The pH was then adjusted to 6.0 with 1 molar 






h. Tris Buffered Saline (TBS) 
TBS was prepared by dissolving 2.43 of Tris-HCl and 8 g of sodium chloride in 
1000 ml of double distilled water with the pH was adjusted to 7.6 by using sodium 
hydroxide. 
i. Tris Buffered Saline/ Tween-20 (TBS-T) 
In this study, TBST was used as washing buffer and antibody diluents. TBST was 
prepared by adding 1 ml of Tween-20 into 1000 ml of TBS prepared before and 
mixed well. The solution was then placed at room temperature. 
 
2.4.3 Protocols involved in IHC 
2.4.3(a) Tissue collection and slide preparation 
The tail arteries were cleaned from fat and rinsed with Krebs solution to prevent the 
presence of hematologic antigens which intervene the detection of target antigens. 
The tail arteries were then cut into 4 to 5 mm in length before immersing them in 
formaldehyde. The purpose of the tissues immersed in 4% of formaldehyde (pH 7.4) 
for 18 to 24 hours to prevent autolysis and also to preserve the tissues.  The 
preserved tissue were then wrapped in the gauze and placed in the cassettes before 
proceeding with tissue processing.  
2.4.3(b) Tissue processing 
 The tissues were then placed in an automated closed tissue processor (Tissue 
processor, TP 1020 Leica) for overnight where the tissues undergo a series of steps 
including dehydration, clearing and infiltrations (Table 2.7.3). The purpose of tissue 








Table 2.7.3 Steps involved in tissue processing 
                 
    
Steps Reagent Time (hour) Process 
1 Formalin 1 Fixation 
2 70% Ethanol 1 Dehydration 
(removing all the water from tissue) 
3 95% Ethanol 1 Dehydration 
4 95% Ethanol 1 Dehydration 
5 100% Ethanol (1) 1 Dehydration 
6 100% Ethanol (2) 1 Dehydration 
       7   100% Ethanol (3) 1 Dehydration 
8 Xylene (1) 1 Clearing 
(traces of alcohol were removed) 
9 Xylene (2) 1 Clearing 
10 Xylene (3) 1 Clearing 
11 Paraffin wax (1) 1 Impregnation 
(to ensure infiltration of paraffin into 
tissues ) 
12 Paraffin wax (2) 1 Impregnation 
13 Paraffin wax (3) 1 Impregnation 
14 Paraffin wax (4) 1 Impregnation 
 
2.4.3(c) Embedding, tissue sectioning and slide preparations 
Following tissue processing, the paraffin-infiltrated tissues were embedded in the 
paraffin mould. The tissues were aligned in the paraffin mould carefully before 
filling them with paraffin wax. The paraffin wax inside the mould was allowed to 
cool on a cold plate until the wax easily detached from the mould. The sides of 
paraffin blocks were then trimmed to remove access paraffin so that it can fix the 
microtome. The prepared blocks were kept in refrigerator prior TO the sectioning. 
This step was to ensure that the blocks were cold enough so that the ribbons from the 
sectioning produced will be smooth and without damaged. Once the block was 
placed in the microtome, the block was trimmed at 5 μm thicknesses. The ribbons 
produced from the block were then floated in a 42°C water bath. The best ribbons of 




poly-L-lysine slides. The slides were then left to dry to remove water that may be 
trapped under the section. Before proceeding to the next step, the slides were heated 
on a hot plate at the temperature of 50°C for 60 minutes 
2.4.3(d) Deparaffinization and rehydrating section 
Prior to staining, the slides need to undergo deparaffinization and rehydrating 
(removing paraffin). Incomplete removal of paraffin can cause poor staining of the 
slides. This method involved several steps described as follows: 
1. The slides were placed in the rack and transferred to xylene I to dewax 
the slides for five minutes in room temperature 
2. The rack was later transferred to different container containing xylene 
II  for another 5 minutes 
3. The rack was later immersed in a container filled with 100% ethanol 
followed by 95%, 80%, 70% and 50% of ethanol respectively for 5 
minutes in each solution. 
4. The rack was then immersed in distilled water, TBS and distilled 
water again for 5 minutes in each solution. 
5. Any excess reagents were drained by tapping the edge of the slide. 
The slides were then immediately subjected to peroxidase quenching 
The slides were not allowed to dry throughout the experiment since drying out can 
causes non- specific antibody and lead to high back ground staining. 
 
2.4.3(e) Peroxidase quenching  
This step was conducted to eliminate endogenous peroxidase activity which may 




peroxidase activity was blocked using 3% hydrogen peroxide in methanol for one 
minute. The slides were then washed 3 times with TBS for two minutes. 
 
2.4.3(f) Antigen retrieval  
Prior to antibody incubation, the step was carried out to reverse the loss of 
antigenicity that might occur during fixation. The formation of methylene bridges 
during fixation can crosslinks the proteins and prevent antibody binding by masking 
the antigenic site.  
In this step, the slides were placed in a glass beaker containing citrate buffer at pH 
6.0. The buffer was let to boil at 95 ° C for 30 minutes. The beaker was then 
removed and the slides were left to cool for 20 minutes at room temperature. The 
slides were then washed with TBS before continuing with antibody incubation. 
 
2.4.3(g) Primary and secondary antibody incubation 
Primary and secondary antibodies were diluted with TBS containing 5% non-fat dry 
milk and 0.1% Tween 20. The antibodies listed in Table 2.7.4 were used. The slides 
were initially incubated with primary antibodies for two hours with at room 
temperature. The slides were then washed with TBST-T for 5 minutes for three times 
before incubating the slides with secondary antibody. The slides incubated with 
secondary antibodies conjugated with HRP for one hour at room temperature. The 







Table 2.7.4 Dilution and duration of incubation for antibodies used in IHC 
Antibodies Dilution Incubation Time 
Anti-Cyclooxygenase 1 antibody 1:200 2 hours 
Anti-Cyclooxygenase 2 antibody 1:200 2 hours 
Anti- Prostaglandin I synthase antibody 1:300 2 hours 
Anti-Thromboxane A2 receptor antibody 1:200 2 hours 
Anti-Thromboxane A2 synthase antibody 1:200 2 hours 
Donkey anti-goat IgG (HRP) 1:200 1 hour 






IP Receptor (Prostaglandin II receptor) 1:200 2 hours 
NOS3 Antibody (eNOS)      1:100           2 hours 
 
2.4.3(h) Slide staining  
The slides were incubated with stable diaminobenzidine (DAB) for 5 minutes and 
then rinsed with deionised water.  
2.4.3(i) Dehydrating and stabilizing with mounting medium 
The slides were placed in a rack and need to undergo dehydration process. This step 
was described as follows: 
1. The rack was transferred to increasing ethanol concentration [70 %, 80%, 
95%, and 100 % (2 times)] by immersing them for 2 minutes in each 
solution.   
2. The rack was later transferred to xylene I and xylene II respectively and was 
left in each solution for 5 minutes. 
3. The slides were taken from the racks and the sections were mounted with 
DPX. 







2.4.3(j) Slide visualization 
The slides were studied under the light microscope for presence of brown colour 
indicating the presence and localization of protein of interest. The colour intensity of 
the protein of interest was compared between the experimental groups by 


























2.5 Statistical analysis 
 Statistical analyses were executed using Statistical Package for Social 
Science (SPSS) Software version 24.0. The normality of data was checked through 
several methods such as histogram with normal curve and Kolmogorov-Smirnov 
test. Normally distributed data were analysed by parametric tests while non-normally 
distributed data was analysed using non-parametric test.  
 In this study, parametric tests were used as the data were normally 
distributed. The one way ANOVA test followed by Bonferroni post hoc was used to 
evaluate the differences between four groups. Paired t-test, a parametric test was 
used to study the differences within the groups before and after treatment. The data 
was reported as means (SD). 
 In functional study, the concentration response curves were calculated and 
presented using the GraphPad Prism Version 5 for Windows (GraphPad Software, 
San Diego, CA, USA). The maximal relaxation (Rmax) and maximal contraction 
(Emax) were chosen as main parameters investigated. The maximal relaxation (Rmax) 
and maximal contraction (Emax) were defined as the utmost relaxation/ contraction to 
the agonist investigated respectively. The figures displayed were reported as means ± 










CHAPTER 3 RESULTS 
 
3.1 Characteristics of Sprague Dawley rats 
3.1.1 Weight measurements  
 Table 3.0 showed the body weight of normal 2-week rats, diabetic-2 week 
rats, normal 10-week rats and diabetic 10-week rats. The mean average initial body 
weight of the rats was 307.75 g. No significant differences were observed between 
the groups. The final body weight measurement was also taken and significant 
differences were noted between the groups. Overall, the normal rats experienced 
weight gains whereas weight losses were noted in diabetic rats.  
  Figure 3.0 showed the difference in body weight before and after 
intervention.  The normal 2-week rats exhibited a significant increase in body 
weight (+ 49.73 g, p<0.001) whereas in diabetic 2-week rats, there was a significant 
decrease in body weight (- 41.67 g, p< 0.05). The same pattern of body weight were 
also observed in normal 10-week rats (+ 143.80 g, p< 0.001) and in diabetes 10- 
week rats (-104.4 g, p< 0.001). Diabetic rats in both groups were also seen to show 












Table 3.0 Initial and final body weights of normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats  
Groups   Initial weight (g) F-statistics (df) p-value Final weight (g) F- statistics (df) p-value 
Normal 2-week rats 303.27 (34.78)  
 












Diabetic 2-week rats 309.33 (44.53) 267.67 (58.01)
a,b,c,
 
Normal 10-week rats 289.93( 64.30) 433.73 (48.96)
a
 
Diabetic 10-week rats 328.47 (34.20) 224.07 (35.93)
a,b,c 
 
Values were presented as mean (SD).  
 
a
 indicates a statistically significant difference within the same group (Paired t-test, p< 0.05).
 b
 indicates significant differences vs. 
diabetic 2-week rats between groups  (ANOVA, p< 0.05); 
c
 indicates significant differences
 
vs. diabetic 10-week rats between groups 
(ANOVA, p< 0.05). 





3.1.2 Fasting blood glucose (FBS) 
Table 3.2 showed the FBS of the four groups after administration of STZ or 
sodium citrate vehicle. FBS in diabetic 2-week rats are higher compared to normal 2-
week rats (p<0.001) and normal 10-week rats (p<0.001). Similar results were also 
seen in diabetic 10-week rats when compared to normal 2-week rats (p<0.001) and 




Table 3.2 FBS of normal 2-week rats, diabetic-2week rats, normal 10-week rats 
and diabetic 10-week rats after STZ or sodium citrate injection  
Groups   FBS (mmol/L) F-statistics (df) p-value 
















Values were presented as mean (SD). Data were analysed using ANOVA 
followed by Bonferroni post hoc test.  
a  
indicates significant differences vs. normal 2-week rats; 
b
 indicates significant 
differences
 





3.2 Contractile responses to KCl and PE  
3.2.1 Contractions to KCl (60mM) in four different groups  
Table 3.3.1 showed contractions to KCl in vessels with or without endothelium. No 



























Table 3.3.1 Contractions to KCl in vessels with or without endothelium in normal 2-week rats, diabetic 2-week rats, normal 10-week 
rats and diabetic-10 week rats 
Type of vessels KCl +EC (mN/mm) F-statistics (df) p-value KCl –EC (mN/mm) F- statistics (df) p-value 
Normal 2-week rats 6.85 (2.04)  
 




6.75 (3.18)  
 




Diabetic 2-week rats 6.05 (2.23) 6.67 (3.51) 
Normal 10-week rats 7.01 (1.35) 5.52 (1.42) 
Diabetic 10-week rats 5.53 (1.70)
 
 5.07 ( 1.17)
 
 
Values were presented as mean (SD). Data were analysed using one way ANOVA followed by Bonferroni post hoc test.   KCl +EC; 





3.2.2 Contractions to PE (10
-4
 M) in four different groups.  
 
 Table 3.3.2 showed the vascular responses to PE (10
-4
 M) in vessels with or 




























Table 3.3.2 Contractions to PE (10
-4 
M) in vessels with or without endothelium in normal 2-week rats, diabetic 2-week rats, normal 10-
week rats and diabetic 10-week rats 
Type of vessels PE +EC (log M/mN) F-statistics (df) p-value PE –EC (log M/mN) F- statistics (df) p-value 
Normal 2-week rats 7.51 (2.77)  
 










Diabetic 2-week rats 6.64 (3.24) 5.95 (2.87) 
Normal 10-week rats 8.23 (2.15) 7.67 (3.64) 
Diabetic 10-week rats 6.25(2.08)
 
 6.59( 1.83) 
Values were presented as mean (SD). Data were analysed by using one way ANOVA followed by Bonferroni post hoc test.  





3.3 Endothelium-dependent relaxation within the groups 
3.3.1 Relative contributions of NO, EDH and prostacyclin in endothelium-
mediated relaxation in normal 2-week rats  
Figures 3.0 showed the maximum relaxations to ACh which specifies the 
contribution of each vasodilator in causing relaxations in normal 2-week rats. 
The overall net response of ACh-mediated relaxation in control solution was 
89.32 (10.03) %. The maximal relaxation caused by NO (vessels incubated with 
indomethacin together with TRAM 34, UCL 1684 and KCl, 30 mM )  was 63.87 
(12.66) % which was highest relaxation when compared with two other vasodilators. 
Percentage relaxation contributed by prostacyclin (vessels incubated with with L-
NAME, TRAM 34, UCL1684 and 30 mM KCl) was 41.26 (9.51) %, which was 
significantly lower compared to NO-mediated relaxation (p<0.001). The EDH-
mediated relaxation was 37.22 (10.65) % and significantly lower compared to 
control solution (p<0.001]. The relaxation of EDH (vessels incubated with L-NAME 
and indomethacin) was significantly lower to NO (p<0.001), but was not 












Figure 3.0 Concentration-response curves of ACh in normal 2-week rats. Arteries 
were incubated with the respective inhibitors initially before subjecting to 
cumulative ACh dose response in order to study the individual contribution of 





indicates significant difference vs. control solution; 
b 
indicates 
significant difference vs. NO-mediated relaxation using ANOVA followed by 










            







C o n tr o l  s o lu t io n
N O -m e d ia te d  r e la x a tio n
E D H -m e d ia te d  re la x a tio n
P r o s ta c y c lin - m e d ia te d  r e la x a tio n



















3.3.2 Relative contributions of NO, EDH and prostacyclin in endothelium-
mediated relaxation in diabetic 2-week rats  
 
Figures 3.1 showed the maximum relaxations to ACh of each vasodilator in 
diabetic 2-week rats 
Overall, the net response of ACh-mediated relaxation in control solution 
was 73.49 (11.05) %. NO-mediated relaxation contributed greatest relaxation which 
was 53.67 (18.01) % when compared with two other vasodilators. The percentage 
relaxation mediated by prostacyclin was 35.10 (14.04) %, which was significantly 
lower than control solution (p< 0.001) and NO-mediated relaxation (p=0.005). The 
relaxation by EDH was 30.13 (13.80) %, which was lower than control solution (p< 





















Figure 3.1 Concentration-response curves of ACh in diabetic 2-week rats. Arteries 
were incubated with the respective inhibitors initially before subjecting to 
cumulative ACh dose response in order to study the individual contribution of 






 indicates significant difference vs. control solution; 
b
 indicates significant 
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3.3.3 Relative contributions of NO, EDH and prostacyclin in endothelium-
mediated relaxation in normal 10-week rats   
Figures 3.2 showed the maximum relaxations to ACh identifying the 
contribution of each vasodilator in causing relaxations in normal 10-week rats.  
The percentage of maximal ACh-mediated relaxation in control solution 
was 86.99 (8.82) %. Maximal relaxation by NO was 55.49 (15.18) % and it was 
significantly lower compared to control solution (p < 0.001). The maximal EDH-
mediated relaxation was 36.53 (15.10) %, which was significantly lower than 
control solution (p <0.001) and NO-mediated relaxation (p= 0.002). Relaxation 
contributed by prostacyclin was 33.70 (13.06) %, which was significantly lower 







Figure 3.2 Concentration-response curves to ACh in normal 10-week rats. Arteries 
were incubated with the respective inhibitors initially before subjecting to 
cumulative ACh dose response in order to study the individual contribution of 
vasodilators. Relaxations are expressed as percentage of the contraction induced by 
PE (10
-4
 M).  
 
a
 indicates significant difference vs. control solution; 
b
 indicates significant 
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3.3.4 Relative contributions of NO, EDH and prostacyclin in endothelium-
mediated relaxation in diabetic 10-week rats  
Figures 3.3 represented the maximum relaxations of each vasodilator in 
causing ACh-mediated relaxations in diabetic 10-week rats. 
The maximal percentage of ACh-mediated relaxation in control solution 
was 58.48 (18.79) %. Maximal NO-mediated relaxation being 31.31 (18.24) % and 
it was significantly lower than control (p <0.001). Maximal relaxation by 
prostacyclin was 20.38 (17.86) % and was reduced when compared to control 
solution (p< 0.001). Maximal relaxation contributed by EDH was 19.80 (18.28) %, 






















Figure 3.3 Concentration-response curves of ACh in diabetic 10-week rats. Arteries 
were incubated with the respective inhibitors initially before subjecting to 
cumulative ACh dose response in order to study the individual contribution of 





indicates significant difference vs. control solution using ANOVA followed by 
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3.4 Endothelium-dependent relaxation between the groups 
3.4.1 Maximal ACh-mediated relaxation in normal 2-week rats, diabetic 2-
week rats, normal 10-week rats and diabetic 10-week rats 
 Figures 3.4 showed the maximal relaxation to ACh in the normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
The maximal relaxation to ACh in normal 2-week rats was 89.32 (10.03) %. In 
diabetic 2-week rats, the maximal relaxation to ACh was 73.84 (11.04) %, which 
was significantly lower compared with normal 2-week rats (p= 0.002) and normal 
10-week rats (p= 0.006). The maximal relaxation to ACh in normal 10-week rats 
was 86.99 (8.82) %.The percentage of maximal relaxation in diabetic 10-week rats 
was 58.48 (18.79) % which were vastly reduced when compared with normal 10-
week (p< 0.001) and normal 2-week rats (p <0.001). There was significant 
reduction in relaxation in diabetic 10-week rats when compared diabetic 2-week 






Figures 3.4 Concentration-response curves to ACh-mediated relaxation in normal 2-
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 




 indicates significant difference vs. normal 2-week rats; 
b
 indicates significant 
difference vs. normal 10-week rats; 
c
 indicates significant difference vs. diabetic 2-
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3.4.2 Maximal NO-mediated relaxation in normal 2-week rats, diabetic-2 week 
rats, normal 10-week rats and diabetic 10-week rats 
 Figures 3.5 showed the maximal relaxation mediated by NO in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats.  
The maximal relaxation contributed by NO in normal 2-week rats was 63.87 
(12.66) %. In diabetic 2-week rats, the maximal relaxation caused by NO was 50.34 
(18.01) %, which was significantly higher than diabetic 10-week rats [Rmax: 50.34 
(18.01) %. vs 31.31 (18.24) %, p< 0.001]. There was a trend of reduced relaxation 
in diabetic 2-week rats when compared to normal 2-week rats (p=0.080). The 
maximal relaxation of NO in normal 10-week rats was 55.49 (15.18) %. The 
maximal relaxation of NO in diabetic 10-week rats was 31.31 (18.24) % which 
were significantly higher lower than normal 2 weeks (p< 0.001) and normal 10 

















Figure 3.5 Concentration-response curves to NO-mediated relaxation in normal 2-
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. The 
vessels were incubated with indomethacin, TRAM 34 plus UCL 1684 and 30 mM 






indicates significant difference vs normal 2-week rats,
 b 
indicates significant 
difference vs. normal 10-week rats,
 c 
indicates significant difference vs. diabetic 10-
week rats using ANOVA followed by Bonferroni post hoc test. There was a trend 
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3.4.2(a) Endothelial nitric oxide synthase (eNOS) protein expression in rat tail 
arteries 
Figures 3.5.1 and 3.5.2 showed the eNOS protein expression, obtained via 
Western blot in tail arteries of normal 2-week rats, diabetic 2-week rats, normal 10-
week rats and diabetic 10-week rats. Expression of eNOS in diabetic 10-week rats 
were significantly lower than normal 2-week rats (p<0.001), normal 10-week rats 
(p<0.001) and diabetic 2-week rats (p=0.023). 
  Plate 3.1 represents immunohistochemical staining highlighting the 
distributions of eNOS in the four groups: The intensity of eNOS protein was low in 
diabetic 10-week rats compared to other groups (normal 2-week rats, diabetic 2-
week rats and normal 10-week rats). 





                                     N2WK             D2WK           N10WK          D10 WK 
                                          
 
                                              
Figure 3.5.1 Representative Western blots illustrating eNOS protein expression in 
tail arteries of normal 2-week (N2WK), diabetic 2-week (D2WK), normal 10-week 
(N10WK) and diabetic 10-week (D10WK) rats. n = 10 rats for each group 
 
Figure 3.5.2: Graphical representation of the eNOS protein expression normalized to 
β-actin. 
a
 indicates significant difference vs. normal 2-week rats; 
b 
indicates 
significant difference vs. diabetic 2-week rats ; 
c 
indicates significant difference vs. 
normal 10-week rats using ANOVA followed by Bonferroni post hoc test. 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 


















































     
Negative control Normal 2-week rats Diabetic 2-week rats Normal 10-week rats Diabetic 10-week rats 
Plate 3.0 Immunohistochemical staining photos of the distributions of eNOS protein expression in the tail arteries of four experimental groups. 
Sections without primary antibodies were used as negative controls. The brown stain indicates expression of eNOS proteins in the vessels (red 




3.4.3 Maximal prostacyclin-mediated relaxation in normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats 
 Figures 3.6 showed the maximal relaxation caused by prostacyclin in normal 2-
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. The 
maximal relaxation by prostacyclin in normal 2-week rats was 41.26 (9.51) %. 
Prostacyclin-mediated relaxation in diabetic 2-weeks rats was 35.10 (14.04) %.  
 Maximal relaxations by prostacyclin in normal 10-week rats was 33.70 (13.05) 
%. Trend of reduction was seen in diabetic 10-week rats (p=0.069) compared to 
normal 10-week rats with no other changes noted in other groups. Prostacyclin-
mediated relaxation in diabetic 10-weeks rats was 20.38 (17.96) %, which were 
significantly lower compared to normal 2-week rats (p <0.001) and diabetic 2-week 
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Figure 3.6 Concentration-response curves to prostacyclin-mediated relaxation in 
normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-
week rats. The vessels were incubated with L-NAME, TRAM 34 plus UCL 1684 
and 30 mM KCl. Relaxations were expressed as a percentage of the contraction 
induced by phenylephrine. 
a 
indicates significant difference vs. normal 2-week rats ; 
b 
indicates significant difference vs diabetic 2-week rats.  
There was a trend of reduction in diabetic 10-week rats when compared to normal 













3.4.3(a) IP receptor protein expression in rat tail arteries 
Figures 3.6.2 and 3.6.3 showed the IP receptor protein expression, obtained 
via Western blot in the tail arteries of normal 2-week rats, diabetic 2-week rats, 
normal 10-week rats and diabetic 10-week rats. Expression of IP receptor protein in 
diabetic 10-week rats were significantly lower than normal 2-week rats (p=0.45), 
normal 10-week rats (p=0.009) and diabetic 2-week rats (p=0.049). 
Plate 3.1 represents immunohistochemical photos highlighting the 
distributions of IP receptor protein in tail arteries of four experimental groups: 
normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week 
rats. The intensity of IP receptor protein was lower in diabetes 10-week rats 
compared to other groups.  
 
 







                        
                                        
 
Figure 3.6.2 Representative Western blots illustrating IP receptor protein expression 
in tail arteries of normal 2-week rats (N2WK), diabetic 2-week rats (D2WK), normal 
10-week rats (N10WK) and diabetic 10-week rats (D10WK). n =10 rats 
 
 
Figure 3.6.3 Graphical representation of IP receptor protein expression normalized 
to β-actin.  
a
 indicates significant difference vs. normal 2-week rats; 
b 
indicates significant 
difference vs. diabetic 2-week rats; 
c 
indicates significant difference vs. normal 10-
week rats using ANOVA followed by Bonferroni post hoc test.. 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 





















































Plate 3.1 Immunohistochemical staining photos showing the distributions of IP receptor in four groups: normal 2-week rats, diabetic 2-week 
rats, normal 10-week rats and diabetic 10-week rats. Sections without primary antibodies were used as negative controls. The brown stain 
indicates expression of IP receptor proteins in the vessels (red arrows). Magnifications 100x.  
     





3.4.3(b) PGIS protein expression in rat tail arteries 
Figures 3.6.4 and 3.6.5 showed the expression of PGIS protein between 
normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week 
rats. The expression of PGIS in in diabetic 10-week rats were significantly lower 
than normal 10-week rats (p<0.001).  
Plate 3.2 represents immunohistochemical photos highlighting the 
distributions of PGIS protein in rat tail arteries of four groups: normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. The intensity of 



























Figure 3.6.4 Representative Western blots illustrating the expression of PGIS 
protein in tail arteries of normal 2-week rats (N2WK), diabetic 2-week rats (D2WK), 
normal 10-week rats (N10WK) and diabetic 10-week rats (D10WK). n = 10 rats 
 
 




indicates significant difference vs. normal 10-week rats using ANOVA followed 
by Bonferroni post hoc test 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 






















































Plate 3.2 Immunohistochemical staining photos showing the distributions of PGIS protein in four groups: normal 2-week rats, diabetic  
2-week rats, normal 10-week rats and diabetic 10-week rats. Sections without primary antibodies were used as negative controls. The 
brown stain indicates expression of PGIS proteins in the vessels (red arrows) .Magnifications 100x. 
     





3.4.4 Maximal EDH-mediated relaxation in normal 2-week rats, diabetic 2-
week rats, normal 10-week rats and diabetic 10-week rats 
 Figures 3.7 showed the maximal relaxation caused by EDH in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats.  
The maximal relaxation contributed by EDH in normal 2-week rats was 37.22 
(10.65) %; whereas relaxation in diabetic 2-week rats was 30.13 (13.80) %. In 
normal 10-week rats, maximal relaxation by EDH was 38.69 (17.71) %. EDH-
mediated relaxation in diabetic 10-week rats was 19.80 (18.28) %. It was 
significantly lower compared to normal 2-week (p= 0.019) and normal 10-week rats 

















Figure 3.7 Concentration-response curves to EDH-mediated relaxations in normal 
2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
The vessels were incubated with L-NAME and indomethacin. Relaxations were 
expressed as a percentage of the contraction induced by PE. 
a
 indicates significant 
difference vs. normal 2-week rats; 
b
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3.5 Endothelium-independent relaxation between the groups 
3.5.1 Maximal-SNP mediated relaxation in normal 2-week rats, diabetic 2-
week rats, normal 10-week rats and diabetic 10-week rats 
 Figures 3.8 showed the maximal relaxation of endothelium-independent 
relaxation due to SNP in normal 2-week rats, diabetic 2-week rats, normal 10-week 
rats and diabetic 10-week rats. 
 The maximal relaxation to SNP in normal 2-week rats was 86.40 (14.02) %. In 
diabetic 2-week rats, the maximal SNP-mediated relaxation was 70.27 (16.87) % 
with no significant differences seen with other groups. The maximal relaxation to 
SNP in normal 10-week rats was 75.56 (21.42) % with no significant differences 
seen with other groups. In diabetic 10-week rats, the maximal relaxation to SNP 
was 59.71 (24.27) %, which was significantly lower than normal 2-week rats [Rmax: 








                                         
 
Figure 3.8 Concentration-response curves to SNP-mediated relaxations in normal 
2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
The endothelial cells were removed from the lumen of the cells by crushing it with 
hair. Relaxations were expressed as a percentage of the contraction induced by PE.
 a
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3.6 Endothelium-dependent contraction within the groups. 
3.6.1 Role of COX, COX-1, COX-2 and TXA2 receptor in endothelium-
dependent contraction in normal 2-week rats        
Figures 3.9 showed maximal contraction (Emax) in the tail arteries of normal 
2-week rats in control solution, or after incubation separately with indomethacin 
(non-selective COX), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 inhibitor) 
or S18886 (TXA2 receptor antagonist). Increases in tension were expressed as 
percentage of the reference contraction to 60 mM KCl obtained at the beginning of 
the experiment.  
The overall endothelium-dependent contraction induced by calcium 
ionophore in solution without presence of blockers (control solution) was 34.80 
(21.06) %. After blocking the vessels with indomethacin (non-selective COX 
inhibitor), the contraction was significantly reduced to 15.18 (12.19) %, (p=0.045). 
The contraction to calcium ionophore was significantly reduced to 14.00 (6.52) % 
when the vessels were incubated with valeryl salicylate (COX-1 inhibitor) 
(p=0.019). Blocking the vessels with NS398 (COX-2 inhibitor) showed no 
significant difference between the control solution. In the vessels incubated with 
S18886 (TXA2 receptor antagonist), the contraction reduced to 15.27 (7.3) %, which 
was significantly lower compared with the vessel in control solution. No differences 
were seen in the contraction to calcium ionophore among vessels incubated with 










Figure 3.9: Concentration-response curves of calcium ionophore in tail arteries of 
normal 2-week rats in the control solution, or incubated with indomethacin (non-
selective COX inhibitor), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 
inhibitor) and S18886 (TXA2 receptor antagonist)                                 
* indicates significant difference vs. control solution using ANOVA followed by 











3.6.2 Role of COX, COX-1, COX-2 and TXA2 receptor in endothelium-
dependent contraction in diabetic 2-week rats         
Figures 4.0 showed maximal contraction (Emax) in the tail arteries of diabetic 
2-week rats in control solution, or after incubation separately with indomethacin 
(non-selective COX), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 inhibitor) 
or S18886 (TXA2 receptor antagonist). Increases in tension were expressed as 
percentage of the reference contraction to 60 mM KCl obtained at the beginning of 
the experiment 
The overall contraction induced by calcium ionophore in solutions without 
presence of blockers (control solution) was 71.80 (46.02) %. However, after 
blocking the vessels with indomethacin (non-selective COX inhibitor), the 
contraction was reduced to 20.01 (18.62) %, (p=0.007). The contraction by calcium 
ionophore in a vessel incubated with valeryl salicylate (COX-1 inhibitor) was 
significantly reduced to 11.00 (9.28) %, (p<0.001) when compared to control 
solution. The contraction contributed by calcium ionophore after blocking the 
vessels with NS398 was significantly reduced to 13.47 (6.51) %, (p=0.002) 
compared to control solution. After the incubation with S18886, the contraction was 












Figure 4.0 Concentration-response curves of calcium ionophore in tail arteries of 
diabetic 2-week rats in the control solution, or incubated with indomethacin (non-
selective COX inhibitor), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 
inhibitor) and S18886 (TXA2 receptor antagonist)                                 
* indicates significant difference vs. control solution using ANOVA followed by 








3.6.3 Role of COX, COX-1, COX-2 and TXA2 receptor in endothelium-  
dependent contraction in normal 10-week rats.          
Figures 4.1 showed maximal contraction (Emax) in the tail arteries of normal 
10-week rats in control solution, or after incubated separately with indomethacin 
(non-selective COX), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 inhibitor) 
or S18886 (TXA2 receptor antagonist). Increases in tension were expressed as 
percentage of the reference contraction to 60 mM KCl obtained at the beginning of 
the experiment.   
The overall endothelium-dependent contraction induced by calcium 
ionophore in control solution was 68.33 (57.80) %. However, after blocking the 
vessels with indomethacin, the contraction was reduced to 17.36 (16.67), (p=0.041).  
After incubating the vessels with valeryl salicylate, the contraction was reduced to 
7.21(7.91) and was significantly lower to contraction in control solution (p=0.010). 
The maximal contraction in vessels blocked by NS398 was significantly reduced to 
12.60 (10.64) %. This contraction was significantly lower than in control solution 
(p=0.021).  The contraction caused by calcium ionophore after incubating the vessels 
with S18886 was 14.53 (12.95) where the contractions were reduced when compared 






Figure 4.1 Concentration-response curves of calcium ionophore in tail arteries of 
normal 10-week rats in the control solution, or incubated with indomethacin (non-
selective COX inhibitor), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 
inhibitor) and S18886 (TXA2 receptor antagonist)                                 
 
* indicates significant difference vs. control using ANOVA followed by Bonferroni 









3.6.4 Role of COX, COX-1, COX-2 and TXA2 receptor in endothelium-
dependent contraction in diabetic 10-week rats 
Figures 4.2 showed maximal contraction (Emax) in the tail arteries of diabetic 
10-week rats in control solution, or after incubated separately with indomethacin 
(non-selective COX), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 inhibitor) 
or S18886 (TXA2 receptor antagonist). Increases in tension were expressed as 
percentage of the reference contraction to 60 mM KCl obtained at the beginning of 
the experiment.  
 The overall endothelium-dependent contraction induced by calcium 
ionophore in solutions without presence of blockers (control solution) was 
113.73(51.32) %. However, after blocking the vessels with indomethacin (COX 
inhibitor), the contraction was reduced to 16.79 (13.28) % which was significantly 
lower when compared to control solution (p<0.001). After incubating the vessels 
with valeryl salicylate, the contraction was reduced to 14.60 (9.87) %. This 
contraction was lower than in control solution (p<0.001).  In vessels incubated with 
NS398, the contraction was significantly reduced to 13.60 (10.05) % compared to 
control solution (p<0.001). When the vessels was incubated with S18886, the 
maximal endothelium contraction was 9.73 (10.94) % where the contractions were 












Figure 4.2 Concentration-response curves of calcium ionophore in tail arteries of 
diabetic 10-week rats in the control solution, or incubated with indomethacin (non-
selective COX inhibitor), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 
inhibitor) and S18886 (TXA2 receptor antagonist)                                 
* indicates significant difference vs. control using ANOVA followed by Bonferroni 













3.7 Endothelium-dependent contraction between the groups. 
3.7.1 Maximal contraction to calcium ionophore in normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
 Figures 4.3 showed maximal contractions (Emax) to calcium ionophore in 
normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-
week rats.   
The maximal contraction in normal 2-week rats was 34.80 (21.0) %.  In 
diabetic 2-week rats, the maximal contraction was 71.80 (46.02) % where there was 
trend in higher contraction when compared to contraction produced by normal 2-
week vessels (p=0.058). The maximal contraction in normal 10-week rats was 
68.30 (57.80)
 
%. In diabetic 10-week rats, the maximal contractions was 113.73 
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Figure 4.3 Concentration-response curves to calcium ionophore in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
*
 indicates 
significant difference vs. normal 2-week rats. There was a trend of increased 
contraction in diabetic 2-week rats when compared with normal 2-week rats 
(p=0.058).                 





3.7.2 Maximal COX-mediated contraction to calcium ionophore in normal 2-
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week 
rats. 
 Figure 4.4 showed the maximal COX-mediated contraction in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. COX- 
mediated contraction was defined as total endothelium-dependent contraction 
produced by calcium ionophore in control solution minus with the contraction 
produced by the vessels incubated with indomethacin.   
 COX- mediated contraction in normal 2-week rats was 19.75 (20.35) %.  In 
diabetic 2-week rats, COX-mediated contraction was 53.00 (41.59) % with trend of 
higher contraction compared to normal 2-week rats (p=0.060). COX-mediated 
contraction in normal 10-week rats was 52.31 (53.03) %. In diabetic 10-week rats, 
COX- mediated contraction was significantly higher than normal 2-week rats [Emax:  
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Figure 4.4 Concentration-response curves to COX-mediated contraction in normal 
2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
Emax was analysed using ANOVA followed by Bonferroni post hoc test. 
*
 indicates 
significant difference vs. normal 2-week rats.  
There was trend of increased contraction in diabetic 2-week rats compared to normal 
2-week rats (p=0.060)          




3.7.3 Maximal COX-1 mediated contraction to calcium ionophore in normal 2-
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week 
rats. 
 Figure 4.5 showed maximal COX-1 mediated contraction in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. COX-1 
mediated contraction was defined as total endothelium-dependent contraction 
produced by calcium ionophore in control solution minus with the contraction 
produced by the vessels incubated with valeryl salicylate. 
 COX-1 mediated contraction in normal 2-week rats was 25.33 (17.52) %.  In 
diabetic 2-week rats, COX-1 mediated contraction was 60.73 (46.23) %, whereas in 
normal 10-week rats, the contraction was 60.40 (58.71) %. In diabetic 10-week rat, 
COX-1 mediated contraction was significantly higher than normal 2-week rats 
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Figure 4.5 Concentration-response curves to COX-1 mediated contraction in normal 
2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
Emax was analysed using ANOVA followed by Bonferroni post hoc test.* indicate 





3.7.3(a) COX-1 protein expression in rat tail arteries 
 
Figures 4.5.1 and 4.5.2 showed the expression of COX-1 protein in tail 
arteries of normal 2-week rats, diabetic 2-week rats, normal 10-week rats and 
diabetic 10-week rats. No significant differences were seen between all experimental 
groups. 
Plate 3.3 represents immunohistochemical staining photos highlighting the 
distributions of COX-1 protein in four groups: normal 2-week rats, diabetic 2-week 
rats, normal 10-week rats and diabetic 10-week rats. No differences were seen in the 























                                    
                                  
                                   
                                          
Figure 4.5.1 Representative of Western blots illustrating the expression of COX-1 
protein in the tail arteries of the normal 2-week rats (N2WK), diabetic 2-week rats 
(D2WK), normal 10-week rats (N10WK) and diabetic 10-week rats (D10WK). 
 n =10 rats 
 
Figure 4.5.2 Graphical representation of the COX-1 protein expression normalized 
to β-actin.  No significant difference was seen between all experimental groups 
 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 













































     
Negative control Normal 2-week rats Diabetic 2-week rats Normal 10-week rats Diabetic 10-week rats 
Plate 3.3 Immunohistochemical staining photos showing the distributions of COX-1 protein in four experimental groups: normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. Sections without primary antibodies were used as negative controls.. The 






3.7.4 Maximal COX-2 mediated contraction in normal 2-week rats, diabetic 2-
week rats, normal 10-week rats and diabetic 10-week rats 
 Figure 4.6 showed maximal COX-2 mediated contraction in normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats.  COX-2 
mediated contraction was defined as total endothelium-dependent contraction 
produced by calcium ionophore in control solution minus with the contraction 
produced by the vessels incubated with NS398. 
 COX-2 mediated contraction in normal 2-week rats was 17.80 (15.37) %.  In 
diabetic 2-week rats, COX-2 mediated contraction was 56.80 (42.12) %, whereas in 
normal 10-week rats, the contraction was 55.20 (57.93) %. In diabetic 10-week rats, 
COX-2 mediated contraction was significantly higher than normal 2-week rats 
[Emax: 99.87 (52.41) % vs. 17.80 (15.37) %, p<0.001]. There were trend of 
increased contraction in diabetic 10-week rats compared to both normal 10-week 
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Figure 4.6 Concentration-response curves to COX-2 mediated contraction in normal 
2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
Emax was analysed using ANOVA followed by Bonferroni post hoc test. 
*
 indicates 
significant difference vs. normal 2-week rats. 
There was a trend of increase contraction in diabetic 10-week rats compared to 
diabetic 2-week rats (p=0.068). Trend of increased contraction was also seen in 







3.7.4(a) COX-2 protein expression in rat tail arteries 
 
Figures 4.6.1 and 4.6.2 showed the expression level of COX-2 protein in tail 
arteries of normal 2-week rats, diabetic 2-week rats, normal 10-week rats and 
diabetic 10-week rats. No significant differences were seen between all experimental 
groups. There was a trend of increased expression of COX 2 in diabetic 10-week rats 
compared to normal 2-week rats (p=0.095). 
Plate 3.4 represents immunohistochemical staining photos highlighting the 
distributions of COX-2 protein in four experimental groups: normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. No differences 






















                                 
                                
 
Figure 4.6.1 Representative of Western blots illustrating the expression of COX-2 
protein in the tail arteries of the normal 2-week rats (N2WK), diabetic 2-week rats 
(D2WK), normal 10-week rats (N10WK) and diabetic 10-week rats (D10WK). 
 n=10 rats 
 
Figure 4.6.2 Graphical representation of the COX-2 protein expression normalized 
to β-actin.   
There was trend of increased expression in diabetic 10-week rats compared to 
normal 2-week rats (p=0.095) 
 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 






























































Plate 3.4 Immunohistochemical staining photos showing the distributions of COX-2 protein in four groups: normal 2-week rats, diabetic 2-week 
rats, normal 10-week rats and diabetic 10-week rats. Negative control was not incubated with primary antibodies. The brown stain indicates 




3.7.5 Maximal TXA2 receptor-mediated contraction in normal 2-week rats, 
diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats 
 Figure 4.7 showed maximal TXA2 receptor-mediated contraction in normal 2- 
week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. 
TXA2 receptor-mediated contraction was defined as total endothelium-dependent 
contraction produced by calcium ionophore in control solution minus with the 
contraction produced by the vessels incubated with S18886. 
 Maximal TXA2 receptor-mediated contraction in normal 2-week rats was 25.13 
(22.13).  In diabetic 2-week rats, TXA2 receptor-mediated contraction was 62.13 
(50.70) % with trend of increased contraction seen compared to normal 2-week rats 
(p=0.090). In normal 10-week rats, the TXA2 receptor-mediated contraction was 
50.47(64.27) %. In diabetic 10-week rats, TXA2 receptor-mediated contraction was 


















                  


































N o r m a l 2 - w e e k s  r a t s
D ia b e tic  2 -w e e k  r a ts
N o rm a l  1 0 -w e e k s  r a t s




                                                                                   
Figure 4.7 Concentration-response curves to TXA2 receptor-mediated contraction 
in normal 2-week rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-
week rats. Emax was analysed using ANOVA followed by Bonferroni post hoc test. 
*indicate significant difference vs. normal 2-week rats 
There was trend of increased contraction in diabetic 2-week rats compared to 





3.7.5(a) TXA2 receptor protein expression in rat tail arteries 
 
Figures 4.7.1 and 4.7.2 showed the expression level of TXA2 receptor protein 
in tail arteries of normal 2-week rats, diabetic 2-week rats, normal 10-week rats and 
diabetic 10-weeks rats. There was a trend of increased expression of TXA2 receptor 
protein in diabetic 10-week rats compared to normal 2-week rats (p=0.083).  
Plate 3.5 represents immunohistochemical staining photos highlighting the 
distributions of TXA2 receptor protein in four groups: normal 2-week rats, diabetic 
2-week rats, normal 10-week rats and diabetic 10-week rats. The intensity of the 























                                       
                                    
Figure 4.7.1 Representative of Western blots illustrating the expression of TXA2 
receptor protein in the tail arteries of normal 2-week rats (N2WK), diabetic 2-week 
rats (D2WK), normal 10-week rats (N10WK) and diabetic 10-week rats (D10WK).  
n =10 rats 
 
 
Figure 4.7.2 Graphical representation of the TXA2 receptor protein normalized to β-
actin. 
 There was a trend of increased expression in diabetic 10-week rats compared to 
normal 2-week rats (p=0.083) 
  
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 
























































     
Negative control Normal 2-week rats Diabetic 2-week rats Normal 10-week rats Diabetic 10-week rats 
Plate 3.5 Immunohistochemical staining photos showing the distributions of TXA2 receptor protein in four groups: normal 2-week rats, diabetic 
2-week rats, normal 10-week rats and diabetic 10-week rats. Sections without primary antibodies were used as negative controls. The brown 





3.7.5(b) TXA2 synthase protein expression in rat tail arteries 
 
Figures 4.7.3 and 4.7.4 showed the expression level of TXA2 synthase 
protein in tail arteries of normal 2-week rats, diabetic 2-week rats, normal 10-week 
rats and diabetic 10-week rats. No significant differences were seen between all 
groups. 
Plate 3.6 represents immunohistochemical photos highlighting the 
distributions of TXA2 synthase protein in four groups: normal 2-week rats, diabetic 
2-week rats, normal 10-week rats and diabetic 10-week rats. No prominent change 























                                           
 
                                         
 
Figure 4.7.3 Representative of Western blots illustrating the expression of the TXA2 
synthase protein in tail arteries of the normal 2-week rats (N2WK), diabetic 2-week 
rats (D2WK), normal 10-week rats (N10WK) and diabetic 10-week rats (D10WK).    
n =10 rats  
 
 
Figure 4.7.4 Graphical representation of the TXA2 synthase protein expression 
normalized to β-actin.  No significant differences were seen between the groups 
N2WK: normal 2-week rats; D2WK: diabetic 2-week rats; N10WK: normal 10-week 































































Plate 3.6: Immunohistochemical staining photos showing the distributions of TXA2 synthase protein in four groups: normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats and diabetic 10-week rats. Sections without primary antibodies were used as negative 





CHAPTER 4  
DISCUSSION 
4.1. General discussion 
In this study, the early (2 weeks) and late (10 weeks) effects of diabetes on 
the individual factor responsible for causing microvascular endothelium-mediated 
relaxation and endothelium-mediated contraction were evaluated. The enzymes and 
receptors involved in mediating these responses were also investigated through the 
methods of Western blotting and immunohistochemistry. Within group analysis of 
endothelium-dependent relaxation showed that NO, prostacyclin and EDH 
contributed to relaxation in normal and diabetic rats. NO is the primary vasodilator 
in all three groups except in diabetic 10-week rats. Significant reduction in ACh-
mediated relaxation was seen as early as 2 weeks after diabetes induction with 
marked impairment noted in diabetic 10-week rats. Also, with the progression of 
diabetes was seen to worsen ACh-mediated relaxation. NO-mediated relaxation was 
blunted in diabetic 10-week rats with a trend of reduced NO-mediated relaxation in 
diabetic 2-week rats (p=0.09). This showed that NO production was affected early in 
diabetes, compared to other endothelium-derived vasodilators. With the progression 
of diabetes, the production of NO was markedly diminished at 10 weeks diabetes. 
Impairment in both EDH and prostacyclin-mediated relaxations were only seen later 
in diabetic 10-weeks rats with no change observed at diabetic 2-weeks rats. Western 
blot and immunohistochemistry results supported the findings of functional studies; 
where the expression and distribution of eNOS protein was significantly lower in 




enzyme were significantly lower in diabetic 10-week rats which are consistent with 
the functional study.  
Endothelium-dependent contraction showed significant increase in diabetic 10-week 
rats with a trend of increase in diabetic 2-week rats (p=0.058) compared to normal 2-
week rats. Within groups analysis showed that endothelium-dependent contractions 
were mediated by COX-1 and TXA2 receptor in all the groups. COX-2 contributes to 
endothelium-dependent contraction in all other three groups (diabetic 2-week rats, 
normal 10-week rats and diabetic 10-week rats) but not in normal 2- week rats. 
Unlike NO, being the predominant vasodilator in endothelium-dependent relaxation 
up until early diabetes and both in normal groups, there were no significant 
difference between contributions of COX-1, COX-2 and TXA2 receptor in 
endothelium-dependent contraction in all the groups. 
Between the groups analysis showed significant increase in endothelium- 
dependent contraction mediated by COX-1, COX-2 and TXA2 receptor in diabetic 
10-week rats compared to normal 2-week rats. Trend of increased endothelium-
dependent contraction mediated by COX (p=0.060) and TXA2 receptor (p=0.090) 
were also seen in diabetic 2-week rats compared to normal 2-week rats. Western blot 
and immunohistochemistry showed no difference in COX-1 protein expression and 
distribution among all the groups. Trend of increased expression of COX-2 and 
TXA2 receptor were seen in diabetic 10- week rats. Findings from this study showed 
that endothelium-dependent contraction increased with the diabetes and this increase 
is mainly due to the increase in both COX-1 and 2 activities together with activation 
of TXA2 receptor that eventually leads to vasoconstriction. Findings from functional 




than endothelium-dependent contractions as microvascular impairment in relaxation 
started to be evidenced early in diabetic 2-week rats. 
 
4.2 Weight measurement, fasting blood glucose and vascular sensitivity to PE 
and KCl contraction 
            In this study, rats from both diabetic groups showed more weight lost 
compared to normal rats. As per our studies, other studies also reported weight lost 
following diabetic inductions (Zhang et al., 2012; Mokhtar et al.2016) indicating 
their diabetic conditions. The fasting blood glucose in both diabetic groups were 
higher compared to the normal groups, which confirmed the diagnosis of diabetes. 
Diabetic rats in both groups were also seen to show polyuria (frequent urination) 
compared to normal rats. This necessitates more frequent bedding change for the 
diabetic rats. STZ which was used to induce diabetes in rats causes the damage to 
pancreatic β cells, resulting in hypoinsulinemia and hyperglycemia. This causes 
insufficient insulin which prevents the body from getting glucose from the blood into 
the body's cells to use as energy. When this occurs, the body starts burning fat and 
muscle for energy, causing a reduction in overall body weight.  
There was no significant difference between normal 2-week, diabetic 2-week, 
normal 10-week and diabetic 10-week rats in their contraction to KCl indicating that 
vascular smooth function were preserved in all the groups. Similarly, contractions to 
PE also showed no significant difference between normal and diabetic groups 







4.3 Endothelium-dependent relaxation 
4.3.1 Within group endothelium-dependent relaxation 
When ACh was introduced to the endothelial cells, it binds to muscarinic 
receptors at the endothelial cells. This causes calcium release from endoplasmic 
reticulum and Ca
2+ 
influx through opening of calcium channel at endothelial cell 
membrane which eventually increases intracellular Ca
2+
 concentration and leads to 
production of vasodilators such as NO, EDH and prostacyclin. The present study 
showed that endothelium-dependent relaxation in the tail arteries of normal-2 week 
rats was mainly mediated by NO; the percentage of NO contributing to 
endothelium-dependent relaxation was 63.87% followed by prostacyclin (41.26%) 
and EDH (37.22%). In diabetic 2-week rats, NO-mediated relaxation was 53.67% 
followed by prostacyclin (35.10 %) and EDH (30.13%). In normal 10-week rats; 
NO was still the main vasodilator contributing to 55.49 % of endothelium-
dependent relaxation followed by EDH (36.53%) and prostacyclin (33.70%). In 
diabetic 10-week rats, there was a significant reduction in endothelium- dependent 
relaxation, where no significant differences were seen among NO (31.31%) 
prostacyclin (20.38%) and EDH (19.80%) indicating that the productions of all the 
vasodilators impaired with diabetes progression. 
This study showed that there were significant differences in NO-mediated 
relaxations compared to prostacyclin and EDH in all three groups: normal 2-week 
rats, diabetic 2-week rats, normal 10-week rats indicating that NO was the 
predominant  vasodilator up until early diabetes rat. However, NO production was 
seen affected with diabetes progression and no longer being the major vasodilator at 
the later stage of disease. No significant difference was seen between relaxation 





4.3.2. Between group endothelium-dependent relaxation  
 4.3.2(a) ACh-mediated relaxation  
 This present study was conducted to evaluate endothelium-dependent 
relaxation in the early phase of diabetes (2 weeks) and late phase of diabetes (10 
weeks). In this study, impairment in endothelium-mediated relaxation started to be 
evident in the microcirculation of Sprague Dawley rats even in the early phase of 
diabetes 2 weeks after diabetes induction. Other than that, this study also showed 
that age did not play an important role in endothelium-mediated relaxation compared 
to rats having diabetes, as there was no significant difference between normal 2-
week and normal 10-week rats. Significant reduction in ACh-mediated relaxation 
between diabetic 2-week and diabetic 10-week rats showing that microvascular 
endothelium-mediated relaxation worsened with the progression of diabetes. The 
impairment in diabetic 10-week rats was more pronounced compared to diabetic 2-
week rats, which was due to the impairment in vasodilation mediated by all the 
vasodilators studied, namely NO, prostacyclin and EDH. 
Impairment in ACh-mediated relaxation in both 2- and 10-week of diabetic 
vessel was consistent with another study conducted by Rodriguez-Manas et al., 
(2003).  In this study, early and intermediate products of non-enzymatic protein 
glycosylation (Amadori adducts), oxidative stress, and endothelial function were 
evaluated in streptozotocin-induced diabetic rat’s mesenteric arteries. Endothelial 
function was tested at several phases of streptozotocin-induced diabetes (from week 
one until nine weeks); impairment in ACh-induced relaxations was seen after 2 
weeks of diabetes both in the mesenteric microvessels and aortic segments. The 




investigated on the role of individual vasodilators which includes NO, EDH and 
prostacyclin whereas the study by Rodriguez-Manas et al.(2003) only evaluated the 
ACh-mediated relaxations. 
  
4.3.2(b) NO-mediated relaxation 
From this study, it can be seen that NO was the major contributor for 
relaxation in all three groups but not during late diabetes. NO contributed 30-65% of 
endothelium-dependent relaxation in the tail arteries of normal and diabetic rats. In 
this study, NO-mediated relaxations were impaired in diabetic 10-week rats 
compared to normal 2-week rats and normal 10-week rats. NO-mediated relaxation 
was also seen to be greatly diminished in diabetic 10-week vessels compared to 
diabetic 2-week showing that with the progression of diabetes; the production of NO 
was severely impaired. A trend of reduced NO-mediated relaxation was also seen in 
diabetic 2-week rats when compared to normal 2-week rats suggesting that 
impairment in NO-mediated relaxation started to occur from the early phase of 
diabetes. This observation is supported by Western blot and immunohistochemistry 
results, where the expression and distribution of eNOS enzyme were significantly 
reduced in diabetic 10-week compared to normal 2-week and normal 10-weeks rats. 
The expression of eNOS was significantly lower in diabetic 10-week compared to 
diabetic 2-week and normal groups. The expression of eNOS was significantly lower 
in diabetic 10-week compared to diabetic 2-week rats showing that reduction in NO 
synthase becomes more pronounced with prolonged duration of diabetes. 
Similar findings were seen by a previous work by Mokhtar et al. (2016). In 
that study, NO-mediated relaxation was impaired and associated with reduced 




performed in six weeks diabetic rats, whereas our studies involved 2 and 10 week of 
diabetic rats evaluating the early and late response of diabetes in the tail arteries.  
The same researcher also reported that NO-mediated relaxation was severely 
impaired in subcutaneous arteries from lower limbs of diabetic patients compared to 
non-diabetic patients (Mokhtar et al., 2014); their functional study results were 
supported by biochemistry results showing lowered eNOS protein expression in the 
arteries of diabetic humans. 
Impairment in NO-mediated relaxation was also seen in another study in 
mesenteric arteries of 10 weeks diabetic rats.  In this study, the researchers reported 
that the expression of total eNOS protein was not different between diabetic and 
normal rats. The total expression of eNOS remained unchanged; however, the dimer 
form of eNOS were significantly reduced in diabetic groups compared to normal rats 
(Leo et al.,2011). eNOS may exist in dimer and monomer forms in the endothelial 
cells. eNOS dimerization is essential to ensure the normal function of eNOS (Chen et 
al., 2014). The dimer form of eNOS is regarded as the active form, whereas the 
monomer form is considered inactive.  In eNOS dimers, one eNOS monomer 
reductase domain transfers an electron to another eNOS monomer's heme center of 
the oxygenase domain, which catalyses the conversion of L-arginine to L-citrulline, 
producing NO. However when the eNOS is in the monomer form, it is not able to 
deliver the electrons to the heme center of another eNOS monomer. This causes the 
electrons to be transferred to a different position on the same eNOS monomer. This 
condition provides the interaction with oxygen and the formation of superoxide 
(O2 
−
) free radicals (Xu et al., 2007; Schulz et al., 2008b; Chen et al., 2014).  In 
Leo’s study, increased superoxide levels was seen in diabetic mesenteric arteries, 




diabetes rats was due to increased superoxide levels which leads to the degradation 
of NO by superoxide (eNOS uncoupling).  The difference between  the current study 
and Leo’s study is the type of vessels studied; we used tail artery instead of 
mesenteric artery. It was reported that the source of NO production differs in 
mesenteric and tail artery (Sousa et al., 2015). In mesenteric artery, NO was mainly 
produced through nNOS pathway, while in tail artery, the synthesis of NO was via 
eNOS pathway. This difference can explain why the total expression of eNOS was 
not affected in Leo’s study, though there was impairment in NO-mediated relaxation.  
There are a number of mechanisms that may contribute to the impairment in 
NO-mediated relaxation in diabetes. Firstly, oxidative stress contributes to the 
inactivation of NO production in the early stage of diabetes and worsened with the 
progression of diabetes. The increase of reactive oxygen species (ROS) can 
contribute to the imbalance between vasodilators and vasoconstrictor mainly by 
inactivating the production of NO (Schieber and Chandel, 2014; Pierini and Bryan, 
2015). A number of enzymes such as NADPH oxidases, xanthine oxidase, and 
enzymes of the mitochondrial respiratory chain are capable of generating ROS 
(Souza et al., 2001; Forstermann and Sessa, 2012; Daiber et al., 2017). NADPH 
oxidases are identified as the primary source for ROS generation (Beswick Richard 
et al., 2001) where it can trigger endothelial NOS (eNOS) uncoupling (Landmesser 
et al., 2003), xanthine oxidase activity (McNally et al., 2003; Landmesser et al., 
2007), and mitochondrial enzymes to produce more ROS (Doughan Abdulrahman et 
al., 2008; Wenzel et al., 2008; Swenja et al., 2014). Studies had shown that the 
production of NO was diminished when the endothelial cells were exposed to 
elevated glucose level (Hoshiyama et al., 2003). During hyperglycaemia in diabetes, 




favour excess generation of ROS (Circu and Aw, 2010). Excess ROS will further 
inactivate NO by rapid oxidation. Besides that, increased production of superoxide 
anion (O2−) and NO cause the formation of peroxynitrite (ONOO−) within the 
vascular wall (Krötz et al., 2004). Formation of peroxynitrite oxidized the NOS 
cofactor, tetrahydrobiopterin (BH4) which is necessary for NO synthesis. The 
presence of both peroxynitrite and superoxide itself can oxidize BH4 leading to BH4 
deficiency (Bagi et al., 2004; Schulz et al., 2008a; Chen et al., 2010b; Gillis et al., 
2018). Apart from that, generation of peroxynitrite also reduced cellular transport of 
L-arginine, an eNOS substrate which further promotes eNOS uncoupling 
(Förstermann and Sessa, 2012). Studies also showed that deficiency of L-arginine 
and overabundance of superoxide affects NO bioavailability (Hoshiyama et al., 
2003; Yang and Ming, 2013). Therefore the production of NO is dependent on the 
availability of BH4 and also L-arginine (Luiking et al., 2012; Yang and Ming, 2013). 
Consequently, all these events will cause eNOS uncoupling which in turn generates 
more peroxynitrite formation and further causes inactivation of NO. 
Secondly, chronic hyperglycemia also increases the formation of advanced 
glycation end products (ADMA) which contributes to endothelial dysfunction (Singh 
et al., 2014). ADMA is a competitive inhibitor of eNOS where the increase in 
ADMA will compete with L-arginine for eNOS binding. This causes eNOS 
uncoupling which leads to NO depletion and an increase in superoxide formation 
(Sydow and Munzel, 2003; Pluta, 2008; Forstermann and Sessa, 2012). The 
formation of ADMA also increases with rising levels of oxidative stress. This might 
be due to the decrease in dimethylarginine dimethylaminohydrolase (DDAH) 
activity which normally degrades ADMA production in the cells (Alacam et al., 




and thus increases ADMA concentration (Leiper et al., 2002). Emerging studies 
suggested that S-glutathionylation of eNOS as another mechanism for eNOS 
uncoupling (Chen et al., 2010a; Guerby et al., 2019). Under oxidative stress, 
cysteine (Cys) residues on eNOS are oxidized, leading to glutathionylation of eNOS 
contributing reduced NO generation.  
Thirdly, hyperglycemia also increases the synthesis of a molecule called 
diacylglycerol (DAG) which further intensifies the activations of PKC kinase 
pathway (Beckman Joshua et al., 2002; Gutterman David, 2002; Brownlee, 2005). 
Several studies showed that stimulation of PKC by DAG causes sudden influx of 
calcium intracellularly which mediates contraction in isolated blood vessels (Khalil 
and van Breemen, 1988; Horowitz et al., 1996; Kanashiro and Khalil, 1998; Khalil, 
2013). PKC activation also turns off the production of eNOS while the production of 
other vasoconstrictors such as Ang II and endothelin increases (Ohara et al., 1994; 
Hirata et al., 1995; Ohara et al., 1995; Brownlee, 2005).  Apart from that, PKC 
activation also causes NO degradation since its activation causes free radical 
generation.  
Finally, recent studies showed that hyperglycemia via activation of the 
hexosamine pathway impaired NO-dependent relaxation. In this pathway, 
hyperglycemia leads to an increase of protein O-GlcNAcylation. O-GlcNAcylation 
of eNOS decreases its activity which leads to depletion of NO-mediated relaxation 
(Beleznai and Bagi, 2012; Issad, 2015; da Costa et al., 2018). It also increases the 
production of superoxide which further impairs the endothelium-mediated relaxation 






4.3.2(c) EDH-mediated relaxation 
           In this study, EDH contributed approximately 19 to 38 % of endothelium-
dependent relaxation in tail arteries of normal and diabetes rats. EDH-mediated 
relaxations were significantly reduced in diabetes 10-week rats when compared to 
both normal groups. Impairment in EDH-mediated relaxation was also seen in other 
studies involving mesenteric arteries (Leo et al., 201,Fukao et al., 1997; Wigg et al., 
2001; Matsumoto et al., 2003b; Matsumoto et al., 2005; Matsumoto et al., 2006b). 
However, in a different study by Mokhtar et al. (2014), EDH-mediated relaxation in 
the tail arteries of SD rats were seen comparable between diabetic and control groups 
which can be related to the duration of diabetes which was six weeks compared to 
our study which was longer than theirs.  In another study, augmented EDH-mediated 
relaxation was seen in mesenteric artery of diabetes rats which was due to the 
compensatory response as the NO-mediated vasodilatation being reduced (Shi et al., 
2006). In Shi’s study, the difference in the variability of vascular parts chosen may 
contribute to the difference in EDH role in relaxation. Besides using mesenteric 
artery, Shi et al. (2006) also investigated the role of EDH in carotid and femoral 
arteries in 12 weeks of diabetic rats. In that study, augmented EDH responses were 
seen in mesenteric and femoral arteries but not in carotid artery. The difference in 
the findings could be due to a number of factors such as different vascular bed 
chosen, duration of diabetes in animal models and severity of hyperglycemia. In the 
current study, the FBG was higher at approximately 30 mmol/L whereas in Shi’s 
study, the FBG level was lower at 20.8 mmol/L. Studies had previously reported that 
severity of hyperglycemia affects EDH-mediated relaxation (Pieper, 1999; 




There are multiple mechanisms that may cause impairment in EDH-mediated 
relaxation in diabetes; the contributing factors are still being studied.  One of the 
mechanisms is via defects in the the adenosine 3’,5’-cyclic monophosphate cyclic 
(cAMP) signalling pathway which abolishes EDH responses. cAMP that is produced 
in endothelial cells disperse to the underlying smooth muscle via myo-endothelial 
gap junctions. This causes hyperpolarisation of the VSMC membrane mainly 
through PKA-dependent activation of K
+
 channels (Garland et al., 2011; Mokhtar 
and Rasool, 2015). cAMP levels was found to be reduced in mesenteric arteries of 
diabetic rats. Abnormalities in the cAMP signalling cause reduction in cAMP levels 
and increase in phosphodiesterase 3 (PDE) activities (Matsumoto et al., 2003b; 
Matsumoto et al., 2006a). The use of PDE inhibitor was seen to supress the PDE 
activity which enhances EDH-mediated vasodilatation (Matsumoto et al., 2003c; S 
Moreira et al., 2018). The reduction in cAMP concentration leads to the impairment 
of EDH-mediated vasodilatation (Matsumoto et al., 2003a). Impairment of cAMP-
mediated vasodilatation most likely occurs due to the decline in PKA activity 
(Matsumoto et al., 2003c; Matsumoto et al., 2004). Hyperglycemia leads to 
modification of PKA content, alterations in its subcellular localization, reduction of 
PKA substrates and decreased or altered β-adrenergic signalling which contributes to 
reduced activity of PKA and consequently abolished EDH-mediated relaxation 
(Matsumoto et al., 2004) 
Diabetes has been shown to increase lysophosphatidylcholine (LPC) (Rabini 
et al., 1994) which inhibited EDH-mediated relaxations (Fukao et al., 1995; 
Matsumoto et al., 2006b). Huge increase of plasma LDL-C in diabetic rats causes 
sudden rise of superoxide anions due to the decreased activity of vascular superoxide 




of superoxide anions in turn oxidizes LDL-C generating LPC (Kobayashi and 
Kamata, 1999). LPC is then transported to the endothelial surface where it prevents 
EDH-mediated relaxation by reducing the endothelial KCa channel activities 
(Matsumoto et al., 2006b). In another study, as a consequence of LPC released from 
oxidized low-density lipoprotein (ox-LDL), the intracellular calcium release and also 
Ca
2+
 influx from the extracellular space were seen compromised in aortic endothelial 
cells from STZ-induced diabetic mice. In this study, LPC was seen to impair EDH-
mediated responses by decreasing endothelial Ca
2+
 rise in STZ-induced diabetes. 
However, the relaxation was improved by lowering plasma LDL level with 
cholestyramine. This study proposed that LPC may have significant role over Ca
2+ 
mobilization in the aortic endothelium of diabetic mice (Kamata and Nakajima, 
1998). 
Other than that, abnormalities or dysregulations in Ca
2+
 signalling pathways 
(reduction in the intracellular Ca
2+
 release and/or extracellular Ca
2+
 influx) in 
endothelial cells has also been reported to be associated with impairment in EDH-
mediated responses. Hyperglycemia increases the production of oxidative stress and 
also stimulates excessive protein kinase C (PKC) activation which in turn causes 
disruption or alteration in intracellular Ca
2+
 mobilization (Kugiyama et al., 1992).  
Besides that, impairment in EDH-mediated relaxation was also linked to 
modification in the function and/or expression of potassium channels (SKCa and 
IKCa channels). Reduced responses to KCa channel activators were seen in 
mesenteric arteries of STZ-induced rodents (Wigg et al., 2001; Morikawa et al., 
2005; Absi et al., 2013). The decrease in the downstream KCa channel activation in 
diabetes vessels can be due to the changes in endothelial Ca
2+
 mobilization (Kamata 




degradation of endothelial glycocalyx (external layer of the endothelial cells) (Dogné 
et al., 2018) may also result in the impairment of EDH-mediated responses through a 
reduction of the SKCa channel input to EDH (Dogné et al., 2016). Again, an 
increase in ROS production is another factor seen to reduce the KCa channel 
function via the downregulation of KCa channel expression in some diabetic 
vascular endothelial cells (Choi et al., 2013a; Choi et al., 2013b). Advanced 
glycation end products (AGEs) is also seen to stimulate ROS generation and reduces 
the KCa channel function by dysregulating the intracellular Ca
2+
 mobilization (Naser 
et al., 2013) or by downregulating the expression of KCa channel proteins (Zhao et 
al., 2014).  
Current studies also proposed that nonselective cation channels of the 
transient receptor potential (TRP) family in endothelial cells may serve a pivotal role 
in agonist-stimulated Ca
2+
 influx where it causes endothelium-dependent 
vasorelaxation (Earley and Brayden, 2015; Behringer and Hakim, 2019; Goto and 
Kitazono, 2019). Recent studies emphasized that the downregulation of endothelial 





impaired endothelium-dependent hyperpolarization (Seki et al., 2017; Boudaka et 
al., 2019; Goto and Kitazono, 2019). The presence of high glucose was seen to 
downregulate the protein expression of TRPV4 channels, thus tempering the agonist-
stimulated Ca
2+
 influx in retinal microvascular endothelial cells (Monaghan et al., 
2015). Protein expression of endothelial TRPV4 channels was also reported to be 
reduced in retinal arterioles (Monaghan et al., 2015) and mesenteric arteries (Ma et 
al., 2013) of STZ-induced diabetic rats, where this expression of protein was linked 





4.3.2(d) Prostacyclin-mediated relaxation 
In this study, prostacyclin-mediated relaxation contributed to only 
approximately 20-45% of endothelium-dependent mediated relaxations in normal 
and diabetic rats. Results from this study showed that prostacyclin-mediated 
relaxation were severely impaired in diabetic 10-week rats when compared with 
normal 2-week rats. A trend of reduced prostacyclin-mediated relaxation was also 
seen between diabetic 10-week rats compared to normal 10-weeks rats. No 
difference was noted in diabetic 2-week rats when compared to both normal groups. 
However significant difference was seen between diabetic 2-week rats and diabetic 
10-week rats indicating that duration of diabetes affects prostacyclin-mediated 
relaxation, where impairment in its relaxation was seen with the progression of 
diabetes. Western blot and immunohistochemistry results showed that both 
expressions of IP and PGIS in diabetic 10-week rats were significantly lower 
compared to normal groups. The expression of IP receptor was significantly reduced 
in diabetic 10-week rats compared to diabetic 2-week rats showing reduction in IP 
receptor occurs with prolonged duration of diabetes. The expression of PGIS in 
diabetic 10-week was significantly lower compared to normal 10-week rats. Several 
studies in human microcirculation (Meeking et al., 2000; Bolego et al., 2006; 
Szerafin et al., 2006; Mokhtar and Rasool, 2015) and large vessels of animal studies 
(Shen et al., 2003; Kamata et al., 2006; Toniolo et al., 2013) showed impairment in 
prostacyclin-mediated relaxation supporting our observation. However, human 
studies were all studied in long term diabetes patients 
However, a study by Mokhtar et al., 2016 reported that prostacyclin-
mediated relaxations are not impaired in the small arteries of STZ-induced diabetic 




related to the duration of diabetes. Mokhtar et al.( 2016) reported that prostacyclin-
mediated relaxation was not impaired in 6 weeks tail artery of STZ diabetes induced 
rats, while the current study was performed in 10 weeks tail arteries. Mokhtar et al., 
(2016b) also reported increase in COX-1 and COX-2 protein expressions in tail 
arteries of diabetic rats compared to controls. Even though no compensatory rise or 
impairment reported in prostacyclin-mediated relaxation in six weeks vessels, an 
increase in both COX-1 and COX-2 expressions in diabetic vessels indicated that 
prostacyclin might be involved in the attempt to preserve vascular relaxation which 
is impaired with the progression of diabetes. Similar to Mokhtar’s study, trend of 
increased expression in COX-2 enzyme seen in diabetic rats which is supported by 
significant increase in COX-2 mediated contraction in diabetic 10-week rats. The 
increase in COX-2 expression in current study may lead to the increase in 
prostaglandin productions that may cause contraction instead of relaxation. The 
increase in COX-2 expression could be due to the increase in inflammation level 
with the progression of diabetes. In the current study, there was no change in COX-1 
expression between all the groups. 
      A study by Kamata et al. (2006) on large vessels showed that apart from NO 
and EDHF, prostacyclin plays a significant role in relaxation in diabetic rats; 
however no contribution of prostacyclin-mediated relaxation was seen in control 
rats. In that study, endothelium-dependent relaxation in the renal vascular arteries 
of STZ-induced diabetic rats was compromised when the vessels treated with 
tranylcypromine (prostacyclin-synthesis inhibitor). That study demonstrated that an 
increase in prostacyclin relaxation may be due to compensatory vasodilatory 
mechanism, when other productions of vasodilators were reduced with the 




    Prostacyclin was also seen to contribute to endothelium-dependent relaxation 
in the aorta of early stage STZ-induced diabetic mice (Shen et al., 2003). In that 
study, an increase in the blood serum of 6-keto-PGF1α (vasodilator prostacyclin) 
was reported in the initial stage of STZ-induced diabetic mice (Shen et al., 2003), 
where this increase was linked to enhanced ACh-induced relaxation. 
 A few mechanisms were suggested to contribute to the impairment of 
prostacyclin-mediated relaxation in diabetes. Firstly, with the progression of 
diabetes, the production of prostacyclin was found to be disrupted which could be 
due to the increasing level of oxidative stress. Hyperglycemia causes the formation 
of peroxynitrite, which prevents the activity of PGIS via tyrosine nitrosylation-
dependent reaction (Cooke and Davidge, 2002; Zou et al., 2002; Zou, 2007; He et 
al., 2010). Endothelium-dependent vasodilation is compromised in mesenteric 
arteries from superoxide dismutase knockout mice (animal model of oxidative 
stress); due to alterations in NOS and prostacyclin-dependent relaxation responses. 
The relaxation was partly normalized after incubation with exogenous SOD (Cooke 
and Davidge, 2003).  
Secondly, under certain circumstances such as ageing and hypertension, 
prostacyclin might cause endothelial contraction instead of relaxation. Prostacyclin 
seems to play a role for contraction which accounts for endothelial dysfunction seen 
in those conditions such as in hypertension (Blanco-Rivero et al., 2005; Gluais et al., 
2005a; Xavier et al., 2008; Vanhoutte Paul, 2011; Liu et al., 2012; Zhou et al., 2013; 
Luo et al., 2016). The contraction, rather than relaxation by prostacyclin may occurs 
because of the low expression or dysfunction of IP receptors; in this situation 




study, where the expression of IP receptors and PGIS were significantly reduced in 
prolonged diabetes. 
 
4.4 Endothelium-independent relaxation: SNP-mediated relaxation  
In this study, SNP was used to determine endothelium-independent 
relaxation. This experiment was carried out to test whether diabetes affects the 
vascular smooth muscle function in early (2 weeks) and late duration (10 weeks) of 
diabetes. In the present study, the response of VSMC to SNP (NO donor) was 
significantly reduced in diabetic 10-week rats compared to normal 2-week rats 
indicating diminished VSMC sensitivity to NO. However, no change was seen in 
diabetic 2-week indicating that VSMC was still preserved in the early phase of 
diabetes. VSMC was also seen not affected following one week of diabetic induction 
in the mesenteric artery (Zhang et al., 2012). Similar findings were also seen in the 
tail arteries of six weeks diabetic type 1 rats (Mokhtar et al.,2016) and also in aorta 
of four weeks type 2 diabetic rats (Viswanad et al., 2006). From this we can 
conclude that a shorter duration of diabetes did not affect the sensitivity of VSMC.  
In this study, SNP-mediated relaxation was seen impaired in diabetes 10-
week rats showing diminished in VSMC sensitivity. This observation was supported 
by other studies that showed impairment in SNP-mediated relaxation in mesenteric 
artery (Zhang et al., 2012) and aorta (Brown et al., 2001; Csanyi et al., 2007) of 
eight weeks diabetic rats. This showed that with diabetes progression, the cylic 
guanosine monophosphate (cGMP pathway) was affected and thereby diminished 






4.5 Endothelium-dependent contraction 
4.5.1 Within group endothelium-dependent contraction 
In this study, calcium ionophore (A23187) was used to evoke endothelium- 
dependent contractions. Calcium ionophore directly causes the entry of calcium ions 
across the vascular membrane where the increase in intracellular calcium ion 
concentration activates phospholipase A2 (PLA2) leading to production of 
arachidonic acids (AA) in endothelium. AA is later catalysed by the cyclooxygenase 
(COX) enzymes to produce prostanoids such as thromboxane A2. TXA2 will then 
diffuse to the underlying vascular smooth muscle to activate TXA2 receptor which 
eventually causes the contraction vascular smooth muscle. An increase in endothelial 
calcium levels is one of the key factors that lead to endothelium-dependent 
contraction.  
  In this study, to investigate endothelium-dependent contraction, the 
experiments were performed in the presence of L-NAME, an NOS inhibitor to 
inhibit NO production thus optimize endothelium-dependent contraction. To 
investigate the involvement of cyclooxygenase enzymes and TXA2 receptor in each 
group, the tail arteries from each group were separately incubated in indomethacin 
(non-selective COX inhibitor), valeryl salicylate (COX-1 inhibitor), NS398 (COX-2 
inhibitor), S18886 (TXA2 receptor antagonist) and the resulting contractions 
measured.  
In normal 2-week rats, the endothelium-dependent contraction by calcium 
ionophore was 34.80%. The contraction was significantly reduced to 15.18% when 
incubated with indomethacin. In the vessels incubated with valeryl salicylate, the 
endothelium-dependent contraction was significantly reduced to 14.00%, whereas no 




COX-2 did not play a significant role in endothelium-dependent contraction in 
arteries of young rats. Inhibition with TXA2 receptor antagonist significantly reduced 
the contraction to 15.27%, indicating that endothelium-dependent contractions 
involved activation of TXA2 receptor. 
In diabetic 2-week rats, the endothelium-dependent contraction induced by 
calcium ionophore was 71.80% which was reduced to 20.01% after blocking with 
indomethacin. The endothelium-dependent contraction by calcium ionophore in a 
vessel incubated with valeryl salicylate was significantly reduced to 11.00%; 
whereas the contraction after blocking the vessels with NS398 was significantly 
reduced to 13.47%.  The endothelium-dependent contraction was significantly 
reduced to 8.13% after blocking with S18886. These findings showed that 
endothelium-dependent contraction with short duration of diabetes involved both 
COX-1 and COX-2, and due to activation of TXA2 receptor. 
The endothelium-dependent contraction induced by calcium ionophore in 
normal 10-week rats was 68.33% which was later reduced to 17.36% after 
incubating with indomethacin.  The endothelium-dependent contraction was reduced 
to 7.21% after blocking with valeryl salicylate. Blocking with NS398 significantly 
reduced endothelium-dependent contraction to 12.60%, indicating that COX-2 play a 
role in endothelium-dependent contraction in normal 10-week. This was in contrast 
with normal 2-week rats where COX-2 was not seen to mediate the endothelium-
dependent contraction.  In normal 10-week rats, COX-2 was seen to contribute to 
endothelium–dependent contraction suggesting that with aging, COX-2 plays a role 
in endothelium-dependent contraction.  After incubating the vessels with S18886, 




 In diabetic 10-week rats, the endothelium-dependent contraction induced by 
calcium ionophore was 113.73% which was reduced to 16.79% after blocking the 
vessels with indomethacin. The endothelium-dependent contraction was reduced to 
14.60% after incubating the vessels with valeryl salicylate while the contraction was 
significantly reduced to 13.60% when incubated with NS398. The endothelium- 
dependent contraction was reduced to 9.73% when the vessel was incubated with 
S18886. 
Overall from the above findings, it was noted that incubation with inhibitors 
of COX-1, COX-2 (except in normal 2-week rats) and TXA2 receptor antagonist 
caused significant reductions in endothelium-dependent mediated contraction 
compared to control solution indicating active involvement of COX enzymes and 
activation of TXA2 receptors in mediating endothelium-dependent  contraction.   
We could not find similar studies that reported on the roles of COX, and 
TXA2 receptor on vascular contraction response in the diabetic microvasculature. 
However, a similar study has been reported in large vessels of rats (Shi et al., 
2007), where endothelium-dependent contraction in the femoral artery was 
mediated by cyclooxygenase products. Shi et al. (2007) reported that endothelium-
dependent contraction to calcium ionophore was increased in diabetic four weeks 
rats; the contraction was prevented by indomethacin and S18886, suggesting that 
endothelium-dependent contraction involved cyclooxygenase enzymes and 
activation of TXA2 receptors.  In twelve weeks of diabetic rats, endothelium-
dependent contraction was augmented which was abolished by indomethacin and 
valeryl salicylate, and not to COX-2 inhibition. This observation was supported by 
their Western blot results where the protein expression of COX-1 was increased, 




seen to cause partial inhibition of the contraction, whereas combination of TXA2 
receptor antagonist with prostaglandin E2 receptor (EP1-receptors) blockers 
abolished the contractions, indicating that the EDCFs activated both TXA2 and 
EP1-receptors. In this current study, COX-1 and COX-2 mediated the endothelium-
dependent contractions in normal 10 weeks and in both diabetic groups. However, 
COX-2 was seen not to mediate endothelium-dependent in normal 2 weeks. This 
current study also showed that TXA2 receptor antagonist abolished the 
endothelium-dependent contraction in all the groups without the need of 
prostaglandin E2 receptor.  These dissimilarities between current study with Shi et 
al.(2007) likely due to the type of the vessels used. In the current study, tail artery 
was used which is considered microvasculature, whereas in their study, femoral 
artery, a large vessel was used. Besides that, in that study, the diabetes duration was 
4 and 12 weeks whereas in our study the duration was 2 and 10 weeks.  
Another study that shared similar findings with Shi, reported that COX-1 
mediated thromboxane dependent contraction in mesenteric arteries of normal 
Wistar Kyoto rats aged between 8 to 10 weeks (Bolla et al., 2004). In this study, 
only COX-1 was seen to mediate the contractions, while COX-2 did not play a 
significant role in endothelium-mediated contraction. The current study also 
supports the findings where only COX-1 was seen to mediate endothelium-
contraction in normal 2-week rats. However, in the current study, in normal 10 
week- rats, both COX-1 and COX-2 were seen to mediate endothelium-dependent 
contraction. The role of TXA2 was also evaluated in Bolla’s study and it was found 
that TXA2 antagonist contributes to partial inhibition of endothelium contraction 
whereas combination use with prostaglandin E2 receptor antagonist fully inhibited 




complete inhibition of endothelium contraction by TXA2 antagonist was seen in 
normal 2-week and normal -10 week rats. The differences between the studies were 
the involvement of COX-2 in normal 10-week rats and complete inhibition by 
TXA2 antagonist in both normal 2-week and normal 10-week rats. These 
differences may be due to the species; current study used Sprague Dawley whereas 
normal Wistar Kyoto was used by Bolla et al. (2004). Besides, in Bolla’s study, the 
mean age of the rats was 9 weeks whereas in the current study, the mean age of 
both rats from normal groups was 13 and 20 weeks which are much older than 
Bolla’s study. In Bolla’s study however, the roles of COX and TXA2 in diabetes 
were not studied, therefore the comparison were only made between normal groups.  
So far, from our knowledge, the roles of COX-1, COX-2 and TXA2 receptors 
on endothelium-mediated contractions in diabetic microcirculations have not been 
reported. No studies also reported regarding early and late effect of diabetes on 
endothelium-dependent contraction in diabetic microvasculature.   
 
4.5.2 Between groups endothelium-dependent contraction  
4.5.2(a) Diabetes increases endothelial contracting factor 
In this study, endothelium-dependent contraction to calcium ionophore was 
augmented in diabetic 10-week rats compared to normal 2-week rats. There was a 
trend of increased contraction in diabetic 2-week rats compared to normal 2-week 
rats (p=0.058). Within group analysis showed that endothelium-dependent 
contraction is mainly mediated by COX products and involved TXA2 activation in 
all the groups. However, COX and TXA2-receptor mediated contractions were seen 
augmented in diabetic-10 week rats compared to normal 2-week rats indicating that 




difference between normal 2-week and normal 10-week rats indicating that up to 10 
weeks, aging do not play a significant role in affecting endothelium-dependent 
contraction. Aging plays a lesser role in affecting endothelium-mediated contraction 
compared to diabetes.  
In diabetic 2-week rats, the trend observed was an increase in endothelium-
dependent contraction together with a significant reduction in endothelium-
dependent relaxation indicating that the microvascular endothelial functions started 
to be disrupted at the early diabetes stage. The augmented endothelium-dependent 
contraction with blunted relaxation response in diabetic 10-week rats showed that 
with the progression of diabetes, the microvascular endothelial function worsened. In 
this study, endothelium-dependent relaxation was seen to be earlier affected 
compared to endothelium-dependent contractions with diabetes progression.   
 There are a number of reasons that may contribute to the increase in 
endothelium-dependent contraction in the microcirculation of diabetes rats. Firstly, 
diabetes reduced the production of individual vasodilators and caused imbalance 
between availability of EDRF and EDCF. This was seen in this study where 
reduction in the production of vasodilators were observed which leads to impairment 
in endothelium-dependent relaxation. In this study, a trend of NO reduction occurs 
since 2 weeks of diabetes, and the impairment worsened at 10 weeks. The expression 
of eNOS was significantly reduced in diabetic 10-week rats causing reduced 
production of NO. Impairment in prostacyclin-mediated relaxation was also seen in 
diabetic 10-week rats with reduced expression of IP receptor and PGIS in diabetic 
10-week rats. Several studies reported that prostacyclin, instead of mediating 
relaxation; it can cause contraction in aging and hypertension by acting on TXA2 




Gluais et al., 2005b). In the current study, prostacyclin-mediated relaxation was 
impaired in diabetic 10-week rats. The augmented endothelium-dependent 
contraction may be due to prostacyclin which may appear as vasoconstrictor in 
diabetic 10-weeks rats.  EDH-mediated relaxation was seen to be abolished in 
diabetic 10-week rats. From the above observations, all individual vasodilators were 
significantly impaired in diabetic 10-week rats with the progression of diabetes. 
These reduction causes disruption between endothelium relaxing and contracting 
factors which eventually favour vasoconstriction and contribute to microvascular 
dysfunction. 
Secondly, diabetes increases the production of oxidative stress via activation 
of protein kinase C (PKC) resulting in overproduction of oxidative stress (Kizub et 
al., 2014). Activation of PKC not only causes impairment in endothelium-dependent 
relaxation but also increases endothelium-dependent contraction mediated by TXA2 
(Hattori et al., 1999; Cosentino et al., 2003; Liu et al., 2009), prostaglandin 
E2 (PGE2) (Cosentino et al., 2003; Ishida et al., 2012) and endothelin (Hattori et al., 
1999). Other than that, oxidative stress was also seen to contribute to impairment in 
endothelial relaxation by inactivating vasodilators besides being one of the major 
sources of endothelium-dependent contraction (Gryglewski et al., 1986; Rubanyi and 
Vanhoutte, 1986; Auch-Schwelk and Vanhoutte, 1992; Tschudi et al., 1996; 
Miyagawa et al., 2007; Macarthur et al., 2008). In a few studies, oxidative stress was 
seen to induce contraction by stimulating the production of prostaglandin E2 and F2a 
which in turn causes endothelium-dependent contractions (Zou et al., 1999; 
Bachschmid et al., 2003; Gluais et al., 2005b). Reactive oxygen species (ROS) also 
acts as endothelial contracting factor in the canine basilar artery (Katusic and 




during oxidative stress diffuse to the underlying VSMC and trigger COX in the 
vascular smooth muscle cells to create more prostanoids which in turn activate TXA2 
receptors (Auch-Schwelk et al., 1989; Katusic and Vanhoutte, 1989; Garcia-Cohen 
et al., 2000; Yang et al., 2002; Wang et al., 2003; Shi et al., 2008). In hypertensive 
animal models such as in mouse aorta and renal arteries of rats, production of ROS is 
seen to be increased which causes endothelial COX-2 to create more ROS and 
prostanoids which consecutively triggers TXA2 receptors to cause VSMC 
contractions (Tang et al., 2007; Tian et al., 2012). When the endothelial cells are 
triggered with ACh or calcium ionophore (A23187), it causes a sudden outburst of 
endothelial free radical (Tang et al., 2007). This outburst is seen to be prevented by 
indomethacin (COX inhibitors) proving that COX is one of the primary sources of 
superoxide anions in endothelial cells (Tang et al., 2007).  This incidence is also 
evidenced in human forearm vasculature, where both COX inhibitors and antioxidant 
inhibit endothelial dysfunction (Virdis et al., 2013). The free radical, hydrogen 
peroxide is also seen to assist the contraction by inhibiting the translocation and 
degradation of TXA2 receptor, increase its density at the vascular cell membrane 
(Feletou et al., 2010). Apart from that, free radicals also play a harmful role by 
catalyzing nonenzymatic peroxidation of arachidonic acid which causes production 
of PG-like compounds known as isoprostanes. During oxidative stress, the 
production of isoprostane surpasses that of COX-derived PGs (Hardy et al., 2000). 
Isoprostanes functions as biomarkers of oxidative stress (Buczynski et al., 2009) and 
also serve as potent endogenous agonist at TXA2 receptor which facilitates 
contractions (Feletou et al., 2010; Bauer et al., 2014) 
Thirdly, apart from TXA2 being one of the products derived from COX 




prostacyclin, prostaglandin D2, prostaglandin E2 and/or prostaglandin F2α, which 
contributes to endothelium-dependent contractions (Ito et al., 1991; Asano et al., 
1994; Ge et al., 1995; Ge et al., 1999; Bos et al., 2004; Hirao et al., 2008; Vanhoutte 
and Tang, 2008). High concentrations of prostacyclin were reported to induce 
contraction of VSMC instead of relaxation through the activation of TXA2 receptors 
in diseased conditions such as hypertension (Ge et al., 1995; Rapoport and Williams, 
1996; Blanco-Rivero et al., 2005; Gluais et al., 2005b). Prostaglandin F2a is also 
found predominantly as EDCF in human renal arteries (Wong et al., 2009; Tian et 
al., 2012). In ageing, it was found that COX-2-derived prostaglandin F2a appear to be 
the main EDCF in the aorta of hamsters (Wong et al., 2009; Wong et al., 2010). 
Therefore, the contribution of each prostaglandin differs amongst species and 
vascular beds. Finally, other endothelial contracting factors such as endothelin and 
angiotensin II (which were not studied in this study) were seen to increase 
endothelial contraction. Endothelin and angiotensin II levels have been reported to 
increase in diabetes (Mather et al., 2002; Chawla et al., 2010). In diabetic rats, 
treatment with endothelin blockers improved diabetes-induced aortic endothelial 
dysfunction (Kanie and Kamata, 2002). Studies also showed that overproduction of 
endothelin in diabetes could be due to the generation of oxidative stress which 
eventually leads to endothelial dysfunction (Amiri et al., 2004). Overexpression of 
endothelin in small resistance arteries demonstrated that diabetes exaggerated 
endothelial dysfunction where decreased in eNOS expression and antioxidant 
capacity were seen with enhanced ROS production (Idris-Khodja et al., 2016). 
Angiotensin II (Ang II) was reported to cause injury to endothelial cells and leads to 
endothelial dysfunction. It induces formation of vascular oxidative stress excessively 




2008). Upregulation of NADPH oxidase causes disruption in homeostatic balance 
where it deplete NO production by generating reactive oxygen species (Ceconi et al., 
2002; Förstermann and Li, 2011; Ramalingam et al., 2017).   
 
4.5.2(b) Duration of diabetes increases endothelium-dependent contraction  
Prolonged diabetes causes augmentation in endothelium-dependent 
contraction. Chronic hyperglycemia for a long period causes the endothelial cells to 
lose the ability to release vasodilators (Hein et al., 2016) which was seen in the 
current study where impairment in endothelium-dependent relaxation in diabetic 10- 
week rats was greater than diabetic 2-week rats. Longer duration of diabetes also 
significantly increased oxidative stress (Yan, 2014). Over time, increased oxidative 
stress may cause permanent impairment of vasodilators functions by turning off their 
production and enhancing the effects of endothelial contracting factors such TXA2, 
angiotensin II and endothelin. In the current study, NO- and prostacyclin-mediated 
relaxation were impaired to a greater degree in diabetic 10-week compared to 
diabetic 2-week rats showing that duration of diabetes affects the involvement of 
vasodilators.    
In the current study, a trend of increased COX-2 mediated contraction was 
observed in diabetic-10 week rats compared to diabetic 2-week rats (p=0.068). This 
showed that COX-2 which is induced by inflammation increases with the 
progression of diabetes. Many studies indicated that inflammation level increases 
with the progression of diabetes (Wellen and Hotamisligil, 2005; Bagi et al., 2006; 
Vinagre et al., 2014; Tsalamandris et al., 2019). Trend of increased in COX-2 




expression of COX-2 will increase the production of prostanoids such as TXA2 
which will act on TXA2 receptors and causes increased contraction 
 
4.5.2(c) Role of COX enzymes and TXA2 receptor in endothelium-dependent 
contraction 
In this study, the contribution of individual COX enzymes and TXA2 
receptor in endothelium-dependent contraction between the four groups were 
evaluated.  
COX-mediated contraction was significantly increased in diabetic 10-week 
rats compared to normal 2-week rats. A trend of increased COX–mediated 
contractions was also seen in diabetic 2-week rats compared to normal 2-week rats 
(p=0.060). These findings showed that the endothelium-dependent contraction was 
largely mediated by COX-products. It also showed that diabetes increases COX-
mediated contractions which worsened with diabetes progression.  
COX-1 mediated contraction was significantly higher in diabetic 10-week 
rats compared to normal 2-week rats.  However, Western blot showed no significant 
difference in the density of COX-1 between diabetic and normal groups. Similar 
observation was seen in another study which reported that upregulation of COX-1 
expression or a greater presence of the protein is not essential for EDCF-mediated 
responses (Tang and Vanhoutte, 2009). The author reported that the augmented 
respond of endothelium-dependent contraction are associated to the VSMC 
sensitivity to the PGH2 and arachidonic acid, but not to an increased expression of 
COX-1 expression (Ge et al., 1999) 
 COX-2 mediated contraction was significantly higher in diabetic 10-week 




mediated contraction was not seen in normal 2-week rats. A trend of increased in 
COX-2 mediated contraction was also seen in diabetic 10-week rats compared to 
normal 10-week rats (p=0.053). Besides that, a trend of increased COX-2 mediated 
contraction was observed in diabetic-10 week compared to diabetic 2-week rats 
(p=0.068). In western blot, a trend of increased expression of COX-2 (p=0.095) was 
seen in diabetic 10-week rats compared to normal 2-week rats indicating that COX-2 
may be upregulated in prolonged diabetes. The increase in the activity and 
expression of COX-2 may be associated with increased inflammation in diabetic 10- 
week rats. These observations were also seen in diabetes animal models involving 
large vessels where enhanced COX-2 activity was seen accompanied by the increase 
in endothelium-dependent contraction (Quilley and Chen, 2003; Guo et al., 2005; Xu 
et al., 2019) and decrease in endothelium-dependent mediated relaxation (Nacci et 
al., 2009; Vessières et al., 2013). COX-2 enzyme is enhanced in inflammation and 
increase in inflammation level increases endothelial dysfunction and is associated 
with cardiovascular diseases.  
TXA2 receptor mediated contraction was significantly higher in diabetic 10-
week rats compared to normal 2-week rats. A trend of increased TXA2 receptor 
mediated contraction was also seen in diabetic 2-week compared to normal 2-week 
rats. This showed that endothelium-dependent contraction was significantly 
increased in diabetic rats and involved TXA2 activation. Western blot showed a trend 
of increased expression in TXA2 receptor in diabetic 10-week rats compared to 
normal 2-week rats, while no significant change was seen in TXA2 synthase enzyme. 
Trend of increased TXA2 expression in diabetic 10-week rats may contribute to more 
vasoconstrictors binding to TXA2 receptors which are in line with increased TXA2 




intensity of TXA2 receptor protein was prominent in diabetic 10-week rats compared 
to other groups. These observations showed that TXA2 receptor significantly 






























5.1 Study conclusion 
In this study, endothelium-dependent relaxation was significantly reduced in 
early diabetes at 2 week after induction. In endothelium-dependent relaxation, all the 
vasodilators investigated (NO, prostacyclin and EDH) contributed to relaxations in 
both normal and diabetic rats. NO is the predominant contributor of endothelium-
dependent relaxation followed by prostacyclin and EDH. A trend of reduced of NO-
mediated relaxation was seen in diabetic 2-week rats; significant reduction in NO-
mediated relaxation was observed in diabetic 10-week rats. Impairment in 
prostacyclin and EDH-mediated relaxations were also seen in diabetic 10-week rats 
although no change was observed in 2 weeks diabetic rats. This shows that NO-
mediated relaxation is impaired very early in diabetes compared to other 
vasodilators. In molecular studies, the expression and distribution of eNOS, IP 
receptor and PGIS were reduced in diabetic 10-week rats which are in line with 
findings of functional study. Endothelium independent-relaxation which indicates 
smooth muscle function was impaired in late diabetes (10 week rats) indicating that 
endothelium-independent relaxation was still preserved in early diabetes, but started 
to be compromised with prolonged diabetes.  
 In this study, at 10 weeks diabetes, increased endothelium-dependent 
contraction was seen indicating that more vasoconstriction responses occur with the 
progression of diabetes.  Functional study showed participation of COX-1 and TXA2 
receptor in mediating endothelium–dependent contraction in all the groups. COX-2 




normal 2-week rats. Thus it appears that endothelium-dependent contraction in 
young normal adult rats does not involved COX-2 mediated contraction.  
Endothelium-dependent contractions mediated by COX-1, COX-2 and TXA2 
receptor were seen increased in diabetic 10-week rats. Prolonged diabetes showed 
upregulation (increased expression) of COX-2 enzyme and TXA2 receptor, as shown 
by increased expression of microvascular tissue COX-2 enzyme and TXA2 receptor, 
which supports the functional observation of increased TXA2 receptor and COX-2 
mediated contractions in diabetic 10-week rats. 
Overall from this study, the productions of individual vasodilators were 
decreased with diabetes progression. Increase in endothelium-dependent contraction 
was seen, where this contraction is mainly mediated by COX- products and involved 
TXA2 activation. This study showed that prolonged diabetes worsened the imbalance 
between vasodilators and vasoconstrictor which favours vasoconstriction and 
eventually leads to impairment in microvascular endothelial function. Over 














5.2 Study Novelty and Possible Clinical Implication 
5.2.1 Endothelium-dependent relaxation  
As far as known, this study would be the first study reporting on the early (2 
weeks) and late effects (10 weeks) of diabetes on endothelial function in the tail 
artery, which represent the microcirculation of rats. Findings from this study show 
that endothelium-dependent relaxation is affected early in diabetes, compared to 
endothelium-dependent contraction.  However, over time, endothelium-dependent 
contraction is also affected. Endothelium-dependent relaxation is worsened with 
progression of diabetes, which is associated with significant reduction in eNOS 
expression.  
 
5.2.2 Endothelium-dependent contraction 
As far as known, this study is the first that showed COX-1 and COX-2 enzymes 
and TXA2 receptor played significant roles in endothelium-dependent contraction in 
microvasculature of diabetes rats, during early and late diabetes. Augmented 
responses in COX-1, COX-2 and TXA2-mediated contractions were seen in late 
diabetes indicating that COX-mediated products are involved as vasoconstrictor 
which worsened endothelial function. This is associated with trend of increased 
vascular expressions in COX-2 enzyme and TXA2 receptor. Increased inflammation 
may be one cause of increased endothelium-mediated contraction in prolonged 








5.2.3 Possible Clinical Implication 
The use of tail arteries, which has been reported similar to distal blood circulation 
of human limbs and digits in terms of the anatomy and reactivity profile, may 
suggest similarities to the microcirculation at the peripheral arteries in diabetes. 
From our study, impairment in endothelium-dependent relaxation with trend of 
increased contraction was seen early in diabetes indicating endothelium dysfunction 
occurs very early in diabetes. As the diabetes duration increases, impairment in 
endothelial function worsened with abolished response in relaxation observed 
together with augmentation in endothelium-dependent contractions.  Therefore, 
early management of diabetes would be useful to prevent and ameliorate early 
endothelial dysfunction and its progression to clinical vasculopathy. In this study, 
endothelium-dependent relaxation was predominantly mediated by the vasodilator 
NO. Interventions that restore the endothelium relaxing factor NO such as life style 
modification which include exercising (Silva Aguiar et al., 2018) should be 
encouraged. Findings from this study also showed that endothelium-dependent 
contraction is mainly mediated by COX products and TXA2-receptor.  Future 
studies exploring ways / interventions to reduce the vasoconstrictor effects of COX, 
and TXA2 receptors without affecting other functions should be explored to 










5.3 Study Limitations and Future Research  
In this study, not all the prostanoids (PGD2, PGF2, and PGE2), oxidative stress and 
other vasoconstrictors such as endothelin and angiotensin were able to be studied 
due to the budget constraints and the enormous amount of work and animals 
involved. These could be performed in future studies to get a clearer picture on the 
contribution of each vasoconstrictor in mediating endothelial mediated contractions 
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